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Phosphatase of regenerating liver 3 (PRL-3), an oncogenic phosphatase, is known to 
exhibit pleiotropic effects in cancer progression, including promoting cell proliferation, 
sustaining cell survival, inducing angiogenesis, and enhancing invasion and metastasis. 
However, the signalling mechanisms of PRL-3 remain largely unknown. Here, PRL-3 
was identified as a novel activator of mTOR. PRL-3 induced an aberrant activation of 
mTOR signalling in cancer cells, as reflected by hyperphosphorylation of the direct 
substrates of mTORC1, 4E-BP1 and p70S6K. Despite growth-suppressing limitations, 
PRL-3 persistently activated mTORC1 in the presence of oxygen, serum, or amino acid 
deprivation. Functionally, PRL-3-mediated activation of mTORC1 resulted in increased 
cell motility, invasiveness, and MMP-2/9 production, suggesting a novel pathway for 
PRL-3-mediated cancer progression via mTORC1 activation. In the second part of the 
study, the mechanism underlying PRL-3-driven mTORC1 activation was characterised. 
PRL-3 was found to use a two-pronged approach in activating mTORC1: 1) increasing 
Rheb-GTP accumulation via activation of AKT-TSC2 signalling, and 2) enhancing Rag 
GTPases-mediated mTORC1 recruitment to lysosomes for Rheb-mediated activation. 
Thus, PRL-3 leads to sustained and efficient mTORC1 activation under both normal and 
stressed conditions. This novel mechanism might explain how PRL-3 promotes cancer 
progression through the mTOR pathway. 
Finally, a protective effect of PRL-3 against CoCl2-induced apoptosis was reported. This 
was p38 MAPK-dependent and mechanistically involved dephosphorylation of the 
pro-apoptotic kinase.  
The findings presented contribute to our understanding of PRL-3 signalling and highlight 
potential targets for therapeutic intervention in PRL-3-driven cancers. 
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1.1. Protein Tyrosine Phosphatases 
Protein phosphorylation is a reversible post-translational modification discovered in the 
1950s (Burnett and Kennedy, 1954; Krebs and Fischer, 1955). It plays a pivotal role in 
the regulation of various biological processes, including metabolism, cell growth, 
proliferation, differentiation, migration, motility, organelle trafficking, immunity, and 
apoptosis (Ubersax and Ferrell, 2007; Zhang, 2005). It has been estimated that as many as 
30% of the cellular proteins encoded in the human genome are regulated by 
phosphorylation (Cohen, 2002). The regulation of protein phosphorylation is coordinated 
by kinases and phosphatases (Hardie, 1990). Protein kinases catalyze the transfer of a 
phosphate group from ATP to its protein substrate while protein phosphatases catalyze 
the removal of the phosphate group from the phosphoprotein to a water molecule (Figure 
1.1). 
Protein phosphatases consist of two large families: protein serine/threonine phosphatases 
(PSPs) and protein tyrosine phosphatases (PTPs). The PSP family contains around 30 
members (Shi, 2009) while the PTP superfamily is comprised of more than 100 members 
(Dewang et al., 2005). The first protein tyrosine phosphatase, PTP1B, was isolated and 
characterized in the late 1980s (Tonks et al., 1988). Subsequently, the family of PTPs 
grew extensively and 107 members were identified (Alonso et al., 2004). All these PTPs 
contain an active site motif C(X)5R (where X represents any amino acid) in the catalytic 
domain, which is termed the phosphate-binding loop (P-loop) or PTP signature motif. 
Despite high sequence variations in the (X)5 segment, the consensus residues of cysteine 
and arginine result in a strictly conserved conformation of the P-loop (Tabernero et al., 
2008). Besides the P-loop, the flexible general acid/base motif (known as WPD-loop) is 
another conserved feature of PTPs (Zhang and Bishop, 2008). 
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These two motifs are required for PTP-mediated catalysis. Generally, the enzymatic 
reaction of PTPs occurs in two distinct steps. In the first step, the cysteine of the P-loop 
carries out a nucleophilic attack on a phosphorous atom of the substrate, creating a 
cysteinyl-phosphate intermediate, while the catalytic aspartate in the WPD-loop functions 
as a general acid, donating a proton to the oxygen of the leaving group. In the second step, 
the same aspartate acts as a general base and facilitates the hydrolysis of the intermediate 
by deprotonating a water molecule, leading to a release of inorganic phosphate and the 
regeneration of the free enzyme (Zhang, 2003). 
 
Figure 1. 1 PPs and PKs maintain homeostasis of protein phosphorylation 
Based on the amino acid composition of catalytic domains and substrate specificity, PTPs 
can be classified into four separate subfamilies: class I cysteine-based PTPs, low 
molecular weight PTPs (LMPTPs), CDC25 phosphatases and Asp-Based PTPs (Alonso et 
al., 2004). Class I cysteine-based PTPs are the largest subfamily, consisting of about 
hundred PTPs, including 38 well-known classical PTPs that are tyrosine specific, and 61 
dual-specific protein phosphatase (DUSPs) which exhibit high diversity in structure, 
function, and substrate specificity. Unlike classical PTPs which only dephosphorylate 
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phosphotyrosine residues (PTyr), DUSPs  can also dephosphorylate 
phosphoserine/threonine residues (PSer/PThr), mRNAs, and phosphoinositides (Alonso et 
al., 2004). 
1.2. Phosphatase of regenerating liver family 
The Phosphatase of Regenerating Liver (PRL) family is a unique class of DUSPs. It 
consists of three members: PRL-1，PRL-2, and PRL-3 (also known as PTP4A1, 
PTP4A2, and PTP4A3 respectively). PRL-1 is the first member to be identified as an 
immediate-early gene highly upregulated in regenerating rat liver after partial 
hepatectomy (Diamond et al., 1994; Mohn et al., 1991). Subsequently, in-vitro 
prenylation screening and database search for PRL-1 homologues led to the identification 
of PRL-2 and PRL-3 (Cates et al., 1996; Zeng et al., 1998). In humans, PRL genes are 
located on different chromosomes, with PRL-1, PRL-2, and PRL-3 localized on 
chromosomes 6q12, 1p35, and 8q24.3 respectively. They code for three small 
phosphatases of around 20kDa, 167 amino acid long for PRL-2, and 173 amino acid long 
for both PRL-1 and PRL-3 (Kozlov et al., 2004). These three PRLs exhibit significant 
amino acid sequence homology: 87% between PRL-1 and PRL-2, 79% between PRL-1 
and PRL-3, and 76% between PRL-2 and PRL-3 (Figure 1.2A). 
Besides primary sequence homology, PRLs also display a high similarity in structural 
and domain features (Rios et al., 2013) (Figure 1.2B). All of them contain the core PTP 
domain, which is made up of the WPD-loop and the P-loop in the N terminus. The 
WPD-loop of PRLs has the conserved sequence WPFDD, which is important for 
substrate recognition and binding. The P-loop of PRLs contains a CVAGLGR motif, 
which is responsible for enzymatic activity. Unlike other PTPs, PRLs have a prenylation 
motif (also known as the CAAX box) at the C terminus. The presence of this motif makes 
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them the only PTPs known to be prenylated (Zeng et al., 1998). Near the C terminus of 
PRLs, there is another motif called the polybasic region (K/R/K/R/R/K), which is thought 
to be involved in prenylation by supplying positive charges (Sun et al., 2007). Protein 
prenylation is a post-translational lipid modification involving the covalent addition of 
either farnesyl or geranylgeranyl isoprenoids to the cysteine residue(s) in the CAAX box. 
This modification is critical for proper function of the CAAX proteins, particularly for 
anchorage to the cellular membrane system (Gao et al., 2009). 
 
Figure 1. 2 Amino Acid Sequence Alignment and motifs of Human PRLs. 
(A): Amino acid sequences of human PRLs. The WPD loop motif, C(X)5R motif, 
polybasic region and the CAAX prenylation motif are boxed in the amino acid sequences. 
(B): Structural model of human PRLs. Key motifs are marked. 
In agreement with this finding, most PRLs localize to the intracellular membrane and 
early endosomes. Blocking prenylation by treatment with FTase inhibitors or deletion of 
the CAAX box leads to nuclear localization of the PRLs.(Zeng et al., 2000). Notably, 
PRL-1 and PRL-3 are expressed in the nucleus under specific conditions or in particular 
tissues (Bessette et al., 2008; Diamond et al., 1994; Fagerli et al., 2008; Kong et al., 2000; 
Liu et al., 2013). The localization of PRL1 and PRL-3 might be cell-cycle dependent. 
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Wang et al showed that in HeLa human cervical cancer cells, PRL-1 localizes to the 
endoplasmic reticulum in non-mitotic cells and to the centrosomes and spindle apparatus 
in mitotic cells (Wang et al., 2002). Similarly, a recent study in OH-2 human myeloma 
cells has also been reported that PRL-3 could shuttle between the nucleus and cytoplasm 
during cell cycle progression (Fagerli et al., 2008). In G0/G1 phase, overexpressed PRL-3 
is mainly found in the nucleus, while in G2M phase, overexpressed PRL-3 is 
predominantly observed in the cytoplasm, implying the importance of PRL-3 in cell cycle 
progression. 
In normal tissues, the PRLs have distinct expression patterns. In situ hybridization 
analysis reveals that PRL-1 mRNA is widely expressed in various human tissues, 
particularly in the small intestine, lung, oviduct, testis, gallbladder, T-lymphocytes, and 
adipocytes (Dumaual et al., 2006). Similarly, high levels of PRL-2 mRNA are nearly 
ubiquitous in human tissues, being absent only in taste buds and highly specialized 
fibrocartilage tissues (Dumaual et al., 2006). This widespread mRNA expression of 
PRL-1 and PRL-2 indicates that they may be implicated in basic processes common to 
most tissues and cell types. However, the protein expression patterns of PRL-1 and 
PRL-2 remain largely unknown due to the lack of highly sensitive antibodies. Unlike 
these two proteins, the expression of PRL-3 is much more restricted. Northern blot 
analysis demonstrated that PRL-3 mRNA expression is primarily observed in the heart, 
skeletal muscle, and pancreas (Matter et al., 2001). Intriguingly, PRL-3 protein is 
detected in the fetal heart, developing vasculature, and pre-erythrocytes, but not in their 
mature counterparts (Guo et al., 2006). These observations suggest a potential role for 




1.3. Regulation of PRL-3 
Despite being the last of the PRLs discovered, PRL-3, so far, is the most attractive and 
well-characterized PRL member. Several reports have shown PRL-3 expression is 
regulated at multiple levels, including DNA, RNA and protein levels (Figure 1.3).  
In most cases, the human PRL-3 is a single-copy gene, which is located on the long arm 
of chromosome 8 and spans 9613 nucleotides. However, elevated copy numbers 
of PRL-3 have also been reported in colorectal cancer with liver metastasis, and in some 
myeloma cell lines (Bardelli et al., 2003; Buffart et al., 2005; Fagerli et al., 2008). This 
copy number amplification was initially thought to be responsible for the high expression 
of PRL-3 in cancers. However, a recent study demonstrates that there is no significant 
correlation between PRL-3 gene amplification and mRNA expression, indicating PRL-3 
expression may be strictly regulated at the transcriptional level (Fagerli et al., 2008). 
The first evidence in support of this is the identification of p53 as a transcriptional 
regulator of PRL-3. p53 can directly bind to PRL-3 and activate its transcription in both 
human and mouse cell lines (Basak et al., 2008). Subsequently, several other transcription 
factors of PRL-3 as well as their corresponding functional promoter binding sites in 
PRL-3 gene were identified (Park et al., 2013a; Xu et al., 2011; Zheng et al., 2011; Zhou 
et al., 2011). These factors include Snail, myocyte enhancer factor 2C (MEF2C), signal 
transducers and activators of transcription 3 (STAT3), and STAT5A. They show great 
specificity and ability to drive PRL-3 expression. In addition, extracellular stimuli 
transduced through growth factor signaling pathways can also affect PRL-3 transcription. 
Treating cells with conditioned media from carcinoma-associated fibroblasts or with 
mitogenic cytokines such as IL-6, TNF, and IL-21, lead to an increased expression of 
PRL-3 (Fagerli et al., 2008; Mollevi et al., 2009; Rouleau et al., 2006). On the other hand, 
suppression of PRL-3 mRNA expression has also been observed. Specifically, 
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transforming growth factor β (TGFβ) inhibits PRL-3 transcription by enhancing the 
binding of Smad transcription factors to PRL-3 promoter sequence, suggesting an 
important role of transcriptional regulation in the expression of PRL-3 (Jiang et al., 
2011). 
 
Figure 1. 3 The regulation of PRL-3 at multiple levels. 
PRL-3 is regulated by genetic amplification, RNA transcription and splicing, protein 




No strict correlation has been found between PRL-3 mRNA and protein levels in cancer 
cell lines, implying that the regulation of PRL-3 also occurs at the translational level 
(Wang et al., 2010). PRL-3 pre-mRNA has 5 exons and alternative splicing of exon 4 
generates two different transcripts, resulting in two PRL-3 protein isoforms (Kozlov et 
al., 2002). Compared to the full-length PRL-3 protein, the spliced variant contains only 
148 amino acids and showed no phosphatase activity (Kozlov et al., 2004). In the 
5’-untranslated region (5’-UTR) of PRL-3 mRNA, there are three GC-motifs 
(GCCCAG), which can be recognized and bound by the poly(C)-binding protein 1 
(PCBP1). PCBP1 is an RNA binding protein that has multiple functions, including 
mRNA stabilization and translational silencing (Choi et al., 2009). The binding of PCBP1 
to the GC-motifs leads to the suppression of PRL-3 protein translation (Wang et al., 
2010). 
PRL-3 protein is also regulated by post-translational modifications (PTMs). PTMs refer 
to the covalent modification of proteins, which have a key role in determining protein 
structure, destination, activity, stability, and function (Wani et al., 2015). At present, 
three PTMs of PRL-3, prenylation, oxidation, and palmitoylation, have been 
characterized. As mentioned previously, the CAAX box of PRL-3 is subjected to 
prenylation. However, in contrast to other PRL members, PRL-3 can only be modified by 
farnesylation but not geranylgeranylation (Zeng et al., 2000). The former modification is 
necessary for proper localization and enzymatic activity of PRL-3 (Fiordalisi et al., 2006; 
Zeng et al., 2000). Additionally, just like the other PTPs, PRL-3 can also be oxidized. 
Upon oxidation, PRL-3 has been shown to lose its catalytic activity (Kozlov et al., 2004). 
Two possible mechanisms for the observed oxidative inactivation of PRL-3 have been 
proposed: i) the formation of a disulfide bond between the catalytically-active cysteine 
(Cys104) and conserved cysteine (Cys49), and ii) the conversion of the 
catalytically-active cysteine (Cys104) to catalytically-inactive glycine, resulting in the 
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loss of PRL-3 function (Orsatti et al., 2009). Besides these modifications, palmitoylation 
of PRL-3 has also been reported. However, the mechanism and function of PRL-3 
palmitoylation needs to be further validated (Nishimura and Linder, 2013). 
1.4. The implication of PRL-3 in cancer progression 
Today, PRL-3 is best known for its involvement in cancer. Many types of cancer exhibit 
highly upregulated expression of PRL-3 and mounting evidence suggests this elevated 
PRL-3 expression is implicated in multiple processes of cancer progression, including 
promoting proliferation, resisting cell death, inducing angiogenesis, and inducing 
invasion and metastasis (Figure 1.4). In the following sections, the detailed biological 
roles of PRL-3 in cancer progression will be reviewed. 
1.4.1. PRL-3 expression in human cancers 
In 2001, PRL-3 was first identified as the only gene whose expression was dramatically 
upregulated in metastases from colorectal carcinomas (CRCs) while being undetectable 
in normal colon epithelia (Saha et al., 2001). Subsequently, this finding was confirmed 
by several groups who found that 11-45% of primary CRCs were PRL-3 positive and 
CRC metastases showed a high expression level of PRL-3 (Bardelli et al., 2003; Hatate 
et al., 2008; Kato et al., 2004; Li et al., 2005; Mollevi et al., 2008; Peng et al., 2004; 
Wang et al., 2007c). Later, the prevalence of PRL-3 in diverse types of cancers and 
metastases was reported, including gastric cancer (Bilici et al., 2012; Hu et al., 2013; 
Xing et al., 2013), breast cancer (Hao et al., 2010; Radke et al., 2006; Ustaalioglu et al., 
2012; Wang et al., 2006), nasopharyngeal carcinoma (Zhou et al., 2009), liver carcinoma 
(Wu et al., 2004), ovarian cancer (Huang et al., 2014; Ren et al., 2009), uveal melanoma 
(Laurent et al., 2011), intrahepatic cholangiocarcinoma (Xu et al., 2010), esophageal 
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squamous cell carcinoma (Liu et al., 2008b; Ooki et al., 2010), oral squamous cell 
carcinoma (Hassan et al., 2011), and endometrioid cancer (Guzinska-Ustymowicz et al., 
2013). These reports revealed that PRL-3 can promote advanced stage disease and/or 
metastasis in cancer and its expression correlated with poor overall survival in a number 
of examined cancers, indicating PRL-3 may be highly involved in tumour progression. 
1.4.2. PRL-3 promotes cell proliferation 
The ability to chronically proliferate is an important characteristic of cancer cell 
malignancy (Hanahan and Weinberg, 2011). Following the discovery of the role for 
PRL-1 in liver cell proliferation (Diamond et al., 1996), PRL-3 was also found to be 
involved in sustaining proliferation in HEK293 human embryonic kidney cells (Matter et 
al., 2001). HEK293 cells expressing PRL-3 grew at a faster rate compared to the cells 
expressing vector control or inactive PRL-3 mutant (C104S). This growth rate could be 
reduced by inhibition of PRL-3 with PTPase inhibitors, confirming the requirement of 
phosphatase activity for PRL-3 mediated enhancement of cell proliferation. Furthermore, 
in vivo xenograft mouse models injected with B16 melanoma cells overexpressing 
PRL-3 showed almost a 3-fold increase in tumour volume compared to control cells (Wu 
et al., 2004). Similarly, ectopic PRL-3 expression in SW480 human colon 
adenocarcinoma, TE5 human esophageal squamous carcinoma, LoVo human colorectal 
adenocarcinoma, TF1 human acute myeloid leukemia, and A2780 human ovarian 
carcinoma cells, enhanced their proliferative ability (Huang et al., 2014; Lai et al., 2011; 
Ooki et al., 2010; Park et al., 2013a; Semba et al., 2010). Conversely, suppression of 
endogenous PRL-3 by RNA interference severely impaired cell proliferation in various 
human ovarian, lung, gastric, esophageal, colorectal, and leukemia cancer cell lines 
(Matsukawa et al., 2010; Ming et al., 2009; Ooki et al., 2010; Park et al., 2013a; Polato 
et al., 2005; Semba et al., 2010; Wang et al., 2008; Zhou et al., 2012a). 
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However, our understanding of the precise mechanism(s) by which PRL-3 promotes cell 
proliferation is still limited. It has been reported that overexpression of PRL-3 in 
HEK293 cells activated Src kinase via suppression of C-terminal Src kinase (Csk), a 
negative regulator of Src (Liang et al., 2008). Furthermore, these observations were also 
confirmed in SW480 colon cancer cells in comparison with their SW620 counterparts 
that possess low PRL-3 levels; SW480 had increased Src activity and low Csk expression. 
Activation of Src initiates a number of downstream signaling pathways that enhance cell 
proliferation (Liang et al., 2007). One of these pathways involves the STAT3 signaling 
cascade. STAT3, a transcription factor widely implicated in cell proliferation, migration 
and invasion, is activated upon PRL-3 expression (Yu et al., 2014). Upon activation, 
STAT3 induces the expression of several microRNAs, such as miR-21, miR-17, and 
miR-19a, which contribute to increased cell proliferation (Zhang et al., 2012b). Another 
downstream signaling pathway involved in PRL-3-mediated upregulation of cell 
proliferation is the nuclear factor-κB (NF-κB) pathway. NF-κB is a protein complex 
found in a vast majority of animal cell types and controls DNA transcription (Jing and 
Lee, 2014). PRL-3 overexpression in LoVo colon cancer cells upregulates the expression 
of KCNN4 in a NF-κB-dependent manner, thereby enhancing cellular proliferative ability. 
Furthermore, PRL-3-induced cell proliferation in LoVo cells was significantly reduced 
upon treatment with specific KCNN4 inhibitor (Lai et al., 2011). Recently, PRL-3 was 
reported to drive cell proliferation in an autophagy dependent manner. Blocking 
autophagy by the knockdown of critical autophagy regulators or treatment with 
chloroquine reduces the ability of PRL-3 to drive cell proliferation in A2780 ovarian 
cancer cells, implying PRL-3 requires a functional autophagy pathway to promote cancer 
proliferation (Huang et al., 2014).  
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A few reports have also surfaced showing no significant role for PRL-3 in cellular 
proliferation. In DLD-1 human colorectal adenocarcinoma and A431 human epithelial 
carcinoma cells, no significant differences in cell proliferation were observed upon 
PRL-3 overexpression (Al-Aidaroos et al., 2013; Rouleau et al., 2006). Furthermore, in 
B16-BL6 mouse melanoma , HCT116 human colon carcinoma, INA-6 human myeloma, 
5-8F, and HONE1 human nasopharyngeal carcinoma cells, knockdown of PRL-3 failed 
to have any obvious effect on their proliferative ability (Fagerli et al., 2008; Polato et al., 
2005; Qian et al., 2007; Zhou et al., 2009). Moreover, in SGC-7901 human gastric cancer 
cells, contrasting data on the role of PRL-3 in regulating cell proliferation further cloud 
our understanding (Li et al., 2006; Sun and Bu, 2012; Wang et al., 2008).  
Taken collectively, although there is mounting evidence that PRL-3 promotes cell 
proliferation, there is still controversy over whether that role is cell type-specific. 
1.4.3. PRL-3 resists cell death 
A distinguishing trait of cancer cells is its innate ability to resist cell death and survive in 
harsh conditions. Apoptosis, a well-known programmed cell death, is essential for 
normal biological development and for maintenance of tissue homeostasis. It serves as a 
natural barrier to cancer development (Hanahan and Weinberg, 2011). Physiological 
stress or internal genomic instability results in apoptosis of the normal cell. However, 
apoptosis can be disrupted when there is an abnormal expression of oncogenic proteins, 
leading to tumour initiation and progression (Lowe and Lin, 2000). 
As an oncoprotein, PRL-3 plays an important role in inhibiting apoptosis of cancer cells. 
PRL-3 was firstly reported to attenuate 5-FU-induced apoptosis in HeLa human epithelial 
carcinoma cells. In this study, PRL-3 was shown to reduce p53 stability by upregulating 
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MDM2 and PIRH2, thereby inhibiting p53-mediated apoptosis (Min et al., 2010). 
Furthermore, depletion of endogenous PRL-3 with siRNA significantly enhances 
5-FU-induced apoptosis in TE8, TE10, TE11, and TE14 human esophageal cancer cells 
(Ooki et al., 2010). Treatment with the PRL-3 inhibitor1-4-bromo-2-benzylidene 
rhodanine induced apoptosis in GCIY, AZ521, SH10, and MKN74 human gastric cancer 
cells. However, in normal skeletal muscle C2C12 cells, which highly express PRL-3, no 
effect was observed (Ooki et al., 2011). This implies PRL-3 expression levels alone are 
not responsible for the observed sensitivity to PRL-3 inhibitor treatment in normal cells, 
and the anti-apoptotic function of PRL-3 may be specific to tumour cells (Ooki et al., 
2011). In line with this, treatment of SCG-7901 gastric carcinoma cells with another 
PRL-3 inhibitor, emodin, downregulated PRL-3 activity with a commensurate increase in 
apoptosis (Sun and Bu, 2012). Besides drug-induced apoptosis, apoptosis induced by 
other stresses, such as UV radiation and growth factor deprivation, was also attenuated in 
PRL-3 expressing FET and GEO human colon carcinoma cells. These cells maintained a 
high activated AKT level, which is believed to be associated with resistance to 
stress-induced apoptosis (Jiang et al., 2011). Similarly, an anti-apoptotic effect of PRL-3 
was also detected in H1299 human lung cancer, TF-1, U937, and ML-1 human acute 
myeloid leukemia (AML) cells (Lian et al., 2012; Park et al., 2013a; Qu et al., 2014). 
TF-1 is a cytokine dependent leukemia cell line requiring additional supplementation of 
cytokines in culture media to sustain cell growth and survival. Lack of cytokine 
supplementation triggers apoptosis in TF-1 cells (Lin et al., 2007). Overexpression of 
PRL-3 was shown to promote cell growth and abrogate apoptosis in TF-1 cells upon 
cytokine deprivation, suggesting an anti-apoptotic role of PRL-3 in AML cells (Park et 
al., 2013a). This process is thought to be mediated by Leo1, a component of RNA 
polymerase II–associated factor (PAF) complex, which is induced upon ectopic PRL-3 
expression. Abrogation of Leo1 removed the protective effect of PRL-3 toward cytokine 
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deprivation in TF-1 cells (Chong et al., 2014). Recently, it was reported that PRL-3 
causes drug resistance, preventing the cancer cell from dying by apoptosis. Ectopic 
PRL-3 expression enhanced the anti-apoptotic machinery to prevent drug cytotoxicity, 
mainly resulting from the activation of STAT5 and AKT, indicating their involvement in 
PRL-3-mediated apoptosis evasion (Qu et al., 2014).  
So far, our understanding of the mechanism involved in PRL-3-abrogated apoptosis is 
minimal. Several key signaling cascades involved in cell growth and survival, such as the 
p53 pathway, PI3K/AKT pathway, and STAT pathway have been reported to be 
aberrantly regulated upon PRL-3 overexpression. Interestingly, PRL-3 has also been 
reported to drive autophagy under starvation conditions in A2780 human ovarian cells 
(Huang et al., 2014). Autophagy is a self-degradation process that occurs in nutrient 
demanding conditions. It leads to increased stress tolerance and protects the cell from 
apoptosis via nutrient recycling (He and Levine, 2010). Thus, this PRL-3-mediated 
autophagy might be critical for its role in apoptosis abrogation. Collectively, PRL-3 
inhibits apoptosis in a number of cancer cells, despite the lack of a precise molecular 
mechanism.  
1.4.4. PRL-3 induces angiogenesis 
During their growth, tumours require an excess amount of nutrients and oxygen, and 
they also need to eliminate metabolic wastes and carbon dioxide. These requirements are 
met by a process known as angiogenesis, an ability to form new blood vessels (Mittal et 
al., 2014). It is a normal and vital natural process in growth and development. In normal 
adult tissues, angiogenesis is largely quiescent or only transiently turned-on. However, 
during tumour progression, angiogenesis is constitutively activated, leading to a constant 
sprouting of new vessels. This provides the sustenance factors for expanding neoplastic 
growth (Hanahan and Weinberg, 2011).  
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Numerous studies have revealed a potential role of PRL-3 in the promotion of tumour 
angiogenesis. In human colorectal cancer patients, high PRL-3 levels were detected in the 
tumour vasculature, including the epithelium and smooth muscle cells, but not in normal 
tissues (Bardelli et al., 2003; Kato et al., 2004). Similarly, breast tumour vasculature also 
shows strikingly higher PRL-3 expression levels (Parker et al., 2004). In line with these 
observations, clinical statistical data reveal a significant association between PRL-3 
mRNA expression and micro-vessel density (MVD) in human hepatocellular carcinoma 
(HCC) and non-small cell lung cancer (NSCLS), raising an intriguing question about the 
role of PRL-3 in tumour angiogenesis (Ming et al., 2009; Zhao et al., 2008). Interestingly, 
high PRL-3 protein levels were detected only in developing blood vessels, but not in 
mature ones, implying that PRL-3 may be involved in the early development of the 
vascular system (Guo et al., 2006). Moreover, PRL-3 expression was shown to be 
dramatically upregulated in human microvascular endothelial cells (HMVEC) and human 
umbilical vascular endothelial cells (HUVEC) exposed to phorbol 12-myristate 
13-acetate (PMA). In addition, these cells were shown to exhibit increased level of tube 
formation, a phenotype associated with angiogenesis (Rouleau et al., 2006). Conversely, 
reduced RPL-3 expression or activity using genetic or pharmacological means led to 
suppression of tube formation, indicating that PRl-3 may play an important role in 
tumour angiogenesis (Xu et al., 2011). 
Angiogenesis is a process controlled by opposing factors, with some promoting and 
others suppressing the development of new vessels (Casey and Li, 1997). In an in vitro 
co-culture system, Chinese hamster ovary (CHO) or DLD-1 cells overexpressing PRL-3 
could redirect the migration of HUVECs towards them, thereby enhancing HUVEC 
vascular formation. Similarly, subcutaneous injection of PRL-3-expressing CHO cells 
into nude mouse leads to a recruitment of host endothelial cells towards the tumour mass, 
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thereby initiating angiogenesis. This pro-angiogenic process can be partially attributed to 
PRL-3-mediated suppression of interleukin-4 (IL-4), a well-known modulator of the 
immune system, which also acts as an inhibitor of angiogenesis (Guo et al., 2006; Volpert 
et al., 1998). Vascular endothelial growth factor (VEGF) is another cytokine that can 
stimulate angiogenesis, and its expression levels significantly correlate with that of 
PRL-3 in NSCLC and endometrial adenocarcinoma (Ming et al., 2014; Ming et al., 2009). 
In A549 lung cancer cells, blocking PRL-3 expression resulted in a decrease in VEGF 
expression (Ming et al., 2009). On the other hand, overexpression of PRL-3 induces 
VEGF expression through upregulation of the ERK signaling pathway, thereby 
facilitating microvascular vessel formation and angiogenesis (Ming et al., 2014). 
Furthermore, in vivo studies have also reported similar results, with VEGF-mediated 
vascular permeability largely attenuated in PRL-3 knockout mice compared to wild type 
mice. Colon tumour tissues derived from PRL-3-deficient mice also showed a reduction 
in tumour microvessel density, suggesting that loss of PRL-3 decreases tumour-driven 
angiogenesis (Zimmerman et al., 2014).  
Collectively, both in vitro and in vivo studies have shown a role for PRL-3 in promoting 
tumour angiogenesis to aid in cancer progression. This PRL-3-triggered angiogenesis 
requires the involvement of the cytokines IL-4 and VEGF. Due to the importance of 
angiogenesis in cancer progression, inhibiting angiogenesis has long been proposed for 
cancer therapy (Noonan et al., 2007). The implication of PRL-3 in angiogenesis provides 
a novel attractive target for cancer treatment through inhibition of angiogenesis. 
1.4.5. PRL-3 enhances cancer invasion and metastasis 
In general, most cells remain confined to their organ of origin where they perform their 
specialized activities. However, cancer cells have acquired the ability to disseminate from 
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their organ of origin to other parts of the body in a process called metastasis (Hanahan 
and Weinberg, 2011). The metastatic cascade involves several steps, including invasion, 
migration, implantation and colonization (Scanlon and Murthy, 1991). The acquisition of 
invasive and motile behavior is the primary step and requires reversible changes in 
cell-cell and cell-extracellular matrix (ECM) adherence (Sahai, 2007). After penetrating 
through the tissue barriers, cancer cells enter the circulatory system and lymphatic system, 
and infiltrate other organs. These disseminated cells that travel through the body are 
capable of establishing new tumours at locations distant from the site of the original 
tumour. Hence, once metastasized, it is difficult to target tumour cells by chemotherapy 
or surgery. This is a significant challenge for cancer therapy, as more than 90% of all 
cancer mortality and morbidity are associated with metastasis (Gupta and Massague, 
2006).  
During the past few years, many studies have shown a correlation between elevated 
PRL-3 expression and increased cancer severity and metastasis. In 2001, PRL-3 was 
found to be the only gene expressed at high levels in all CRC liver metastases examined, 
and at low levels in matched non-metastatic tumours and normal colorectal epithelium 
(Saha et al., 2001). Subsequently, various groups confirmed PRL-3 was dramatically 
elevated in CRC metastases in liver, and also in secondary CRC lesions found in the lung, 
brain, ovary, peritoneum, and lymph nodes (Bardelli et al., 2003; Kato et al., 2004; Peng 
et al., 2004; Wang et al., 2007c). Moreover, clinical statistical analysis revealed that high 
PRL-3 expression is associated with increased liver and lung metastasis in colorectal 
cancer, implying that PRL-3 expression might be important for CRC metastasis (Kato et 
al., 2004; Peng et al., 2004). Similarly, in human gastric carcinoma, PRL-3 expression 
levels are much higher in metastatic lesions compared to their corresponding primary 
tumours (Miskad et al., 2004). This increased PRL-3 expression is correlated with 
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increased lymphatic and venous invasion, lymph node and peritoneal metastasis, as well 
as increased tumour stage (Li et al., 2007; Miskad et al., 2007). In addition to CRC and 
gastric carcinoma, breast, lung, esophageal cancers and melanoma also exhibit a strong 
correlation between high PRL-3 expression levels and distant metastasis (Hao et al., 2010; 
Laurent et al., 2011; Lou et al., 2012; Ming et al., 2009; Ooki et al., 2010; Radke et al., 
2006). Notably, analysis of the global gene expression profiles comparing uveal 
melanoma patients with and without liver metastases identified PRL-3 as the only gene 
specifically upregulated in tumours from patients who developed liver metastasis 
(Laurent et al., 2011). These observations strongly indicate the involvement of PRL-3 in 
metastasis. 
To understand the significance of PRL-3 in metastasis, several cell lines and mouse 
models have been employed. In CHO cells, stable expression of PRL-3 enhanced cell 
migration, as detected by wound healing and trans-well assays; and increased cell 
invasion as determined in matrigel trans-well assays. Additionally, in vivo metastasis 
assays revealed that overexpression of PRL-3 in CHO cells induced metastatic tumour 
formation in mice, with the development of lung and liver metastases (Zeng et al., 2003). 
Furthermore, PRL-3 catalytic activity was found to be essential for tumour progression 
and metastasis (Guo et al., 2004). In good agreement with this, overexpression of PRL-3 
in B16 melanoma cells was shown to enhance their migration, adhesion, invasion, and in 
vivo metastatic tumour formation abilities (Wu et al., 2004). Conversely, ablation of the 
expression or activity of PRL-3 reduces metastasis-associated properties in melanoma, 
gastric carcinoma, colon carcinoma, and breast carcinoma cells, indicating specific 
targeting of PRL-3 as a potential effective treatment option for PRL-3 positive human 
cancers (Fagerli et al., 2008; Kato et al., 2004; Li et al., 2006; Qian et al., 2007; Rouleau 
et al., 2006; Wu et al., 2004). Notably, compared with wild type mice, PRL-3 deficient 
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mice developed 50% fewer colon tumours when treated with mutagens such 
asazoxymethane (AOM) and dextran sodium sulfate (DSS); this strongly supports the 
critical role of PRL-3 in tumour formation (Zimmerman et al., 2013). Collectively, these 
studies indicate that specific targeting of PRL-3 may be an effective therapeutic strategy 
for treating PRL-3 positive human cancers. 
The molecular mechanism behind PRL-3 enhanced metastasis is largely unknown. 
However, PI3K/Akt, integrin/Src and Rho family GTPases signaling pathways have been 
reported to mediate some pro-metastasis effects of PRL-3. The PI3K/Akt pathway is an 
important oncogenic pathway that is frequently hyper-activated in human cancers, 
contributing to tumour development, including cell survival, proliferation, invasion, 
migration, and metastasis (Zhang et al., 2015). Overexpression of PRL-3 has been shown 
to activate the PI3K/Akt signaling pathway (Jiang et al., 2011; Lee et al., 2012; Wang et 
al., 2007a). Concomitant with Akt activation, PRL-3 also promotes 
epithelial-mesenchymal transition (EMT) (Wang et al., 2007a). EMT is a process by 
which epithelial cells transform to a more mesenchymal phenotype over a period of time, 
a crucial step in the initiation of the metastasis cascade (van Zijl et al., 2011). Generally, 
it is characterized by loss of adhesion of epithelial cells through disruption of the 
assembly and stability of the adherens junction complexes, thus promoting migratory 
capacity and invasiveness of the cells (Kalluri and Weinberg, 2009). In DLD-1 colorectal 
cancer cells, overexpression of PRL-3 reduces the expression of epithelial marker 
proteins E-cadherin, γ-catenin, and integrin β3, and increases the expression of 
mesenchymal marker proteins Snail and fibronectin, strongly indicating a role for PRL-3 
in triggering EMT (Wang et al., 2007a). In line with this, PRL-3 was also shown to 
induce EMT in SW480 cells both in vivo and in vitro (Liu et al., 2009). Furthermore, 
treating PRL-3 overexpressing cells with the PI3K inhibitor LY294002 mitigates the 
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EMT process, strongly suggesting that PRL-3-induced EMT requires PI3K/Akt activation 
(Wang et al., 2007a). 
Another PRL-3 effector pathway in metastasis is the integrin/Src pathway, a key 
regulator in EMT and focal adhesions (Playford and Schaller, 2004). Focal adhesions are 
dynamic sub-cellular structures composed of multi-protein complexes that mediate the 
attachment of cells to the ECM. The regulation of their formation and disruption is a 
requisite for mestastasis (Campbell, 2008). In mammalian cells, PRL-3 can interact with 
integrin α1 and integrin β1 (Peng et al., 2006; Peng et al., 2009). These two proteins are 
transmembrane receptors considered as bridges for cell-cell and cell-ECM interactions. 
Activation of integrins leads to the recruitment of a plethora of adaptors, kinases, and 
other signaling proteins to focal adhesion complexes, all aiding in cellular migration (Eke 
and Cordes, 2015). In LoVo cells, expression of PRL-3 enhanced Erk1/2 and matrix 
metalloproteinase (MMP2) activities, leading to an increase in cell migration, invasion, 
and metastasis. Furthermore, depletion of integrin β1 abrogates these PRL-3-induced 
phenotypic changes, suggesting the involvement of integrin β1 in PRL-3-mediated cell 
motility and metastasis (Peng et al., 2009). In addition, PRL-3 was shown to regulate the 
activity of Src protein, a key downstream effector of integrin signaling (Mitra and 
Schlaepfer, 2006). In HEK-293 cells, overexpression of PRL-3 activated Src through 
downregulation of Csk, a negative regulator of Src, leading to an increase in cell invasion 
and proliferation (Liang et al., 2007). Some of the direct substrates of Src, such as 
STAT3 and p130
Cas
, were also activated in PRL-3 expressing cells (Liang et al., 2007). 
p130
Cas
 is a scaffold protein that plays a critical role in focal adhesion formation 
(Nakamoto et al., 1997). Overexpression of PRL-3 induced phosphorylation of p130
Cas
 
resulting in the establishment of an interaction between p130
Cas
 and the focal adhesion 
protein vinculin (Nakamoto et al., 1997). This PRL-3 mediated enhancement of focal 
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adhesions and cell motility was eliminated upon introduction of Csk in PRL-3 expressing 
HEK 293 cells, indicating that PRL-3-mediated promotion of focal adhesions required 
the activation of the Src pathway (Liang et al., 2007). However, in contrast to this finding, 
expression of PRl-3 reduced paxillin and vinculin levels in HeLa and CHO cells (Wang 
et al., 2007a). These two proteins are components of focal adhesions, suggesting a role 
for PRL-3 in reducing focal adhesions in HeLa and CHO cells. The contrast in behavior 
of PRL-3 from these two reports might be a result of cell type differences or dynamic 
focal adhesion turnover, as both focal adhesion formation and disassembly are important 
for cell spreading and migration. 
Besides the involvement of Akt and integrin/Src pathways, Rho family GTPases have 
also been reported to regulate PRL-3-induced metastasis. Rho GTPase, such as Rho, Rac, 
and Cdc42, are critical regulators of actin polymerization, stress fiber assembly, focal 
adhesion formation, and cell motility (Parsons et al., 2010). In SW480 colorectal 
carcinoma cells, ectopic PRL-3 expression induced a robust activation of the Rho family 
GTPases RhoA and RhoC by over 4- to 6-fold, and reduced Rac activity by 70% 
(Fiordalisi et al., 2006). Consistent with these results, the observed increase in cell 
migration and invasion upon ectopic PRL-3 expression was reversed with 
pharmacological inhibition of Rho-coiled coil kinase (ROCK), a key Rho effector 
(Fiordalisi et al., 2006). Furthermore, depletion of PRL-3 levels in A549 lung cancer cells 
reduced RhoA activity and mDia1 expression, leading to inhibition of cell migration and 
invasion (Jian et al., 2012). Blocking RhoA or mDia1 showed a reduction in migration 
and invasion, which was alsoobserved on inhibiting PRL-3, suggesting an involvement of 
RhoA, RhoC, and mDia1 in mediating PRL-3-promoted cell migration and invasion. 
However, in contrast to these observations, it was also reported in CHO and DLD-1 cells 
that RhoA and Rac1 expressions were reduced upon PRL-3 expression (Wang et al., 
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2007a). As discussed above, the distinct observations of these two groups may reflect the 
role of enhanced dynamic focal adhesion turnover in promoting cell migration and 
invasion. 
Recent reports have shown that PRL-3 also affects Arf1 protein, microRNAs, and 
calcium channels to regulate metastasis. Arf1 is a member of Arf family GTPases. 
Together with the Rho family GTPases, the Arf family GTPases play a key role in actin 
cytoskeleton remodeling and cell migration (D'Souza-Schorey and Chavrier, 2006). In 
HeLa cells, PRL-3 overexpression increased Arf1 activity, leading to increased cell 
migration. Blocking the expression or activity of Arf1 completely abrogated the 
pro-migratory effect of PRL-3, suggesting that PRL-3-mediated migration requires Arf1 
activation (Krndija et al., 2012). Additionally, PRL-3 elevated the expression levels of 
miR-17, miR-19a, and miR-21 in CRC cells, resulting in an enhancement of metastasis 
(Zhang et al., 2012b). In LoVo colon cancer cells, PRL-3 upregulated the expression of 
KCNN4 channels to increase the expression of Snail and downregulate the expression of 
E-cadherin, leading to EMT. The EMT process was reversed on suppression of KCNN4 
expression or activity, indicating KCCN4 might be implicated in mediating PRL-3- 
induction of EMT and promotion of cancer metastasis (Lai et al., 2013).  
Taken together, PRL-3 promotion of tumour metastasis is quite dynamic and complex. 
Many signaling pathways are involved in this process, which requires activation of 
different effector proteins. Despite these advances in our understanding of PRL-3 
function, the detailed mechanisms and direct substrates are still an open area to be 
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1.5 Proposed substrates of PRL-3 
Despite achievements in elucidating the role of PRL-3 in cancer progression and in 
identifying its associated signaling pathways, a gap remains in our understanding of its 
molecular mechanism(s) of action. This is compounded by the lack of well-characterized 
substrates. To date, a number of PRL-3 binding partners have been reported (Table 1.1). 
However, only a few of them have been confirmed as putative PRL-3 substrates. 
The first suggested substrate of PRL-3 is Ezrin, a linker protein between the plasma 
membrane and the actin cytoskeleton (Forte et al., 2008). In HCT116 colon cancer cells, 
PRL-3 overexpression reduces Ezrin phosphorylation at the Tyr145, Tyr353, and Thr567 
residues. However, knockdown of PRL-3 only affects Ezrin phosphorylation at position 
Thr567. In line with this observation, an in vitro phosphatase activity assay also suggests 
Ezrin as a direct substrate of PRL-3, and Thr567 as the primary site for PRL-3 activity 
(Forte et al., 2008; Orsatti et al., 2009). In addition to Ezrin, elongation factor 2 (EF2) 
was also identified as another potential substrate of PRL-3 (Orsatti et al., 2009). EF2 is a 
protein synthesis regulator that promotes the GTP-dependent translocation of ribosomes 
(Kaul et al., 2011). PRL-3 expression has been shown to suppress EF2 phosphorylation 
(Orsatti et al., 2009). In addition, Keratin 8 (KRT8), Nucleolin (NCL), Integrin β1, and 
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phosphatidylinositol-(4,5)-bisphosphate (PIP2) have also been suggested as possible 
substrates of PRL-3. KRT8 is a member of the intermediate filament family, which plays 
an important role in maintaining cellular structural integrity (Khapare et al., 2012). In 
SW480 colon cancer cells, PRL-3 interacts and dephosphorylates KRT8 at the Ser73 and 
Ser431 residues, resulting in dysregulation of intermediate filament disassembly 
(Mizuuchi et al., 2009). Similarly, NCL protein, a phosphoprotein involved in rRNA 
synthesis and ribosome biogenesis, could also be dephosphorylated by PRL-3, leading to 
its accumulation in the nucleolus (Semba et al., 2010; Tajrishi et al., 2011). Interestingly, 
in vitro phosphatase activity assays also reveals that PRL-3 is active towards 
phosphoinositide PI(4,5)P2, indicating a lipid phosphatase role for PRL-3 (McParland et 
al., 2011). Another putative substrate for PRL-3 is the Integrin β1. In BGC823 and 
SW480 cancer cells, Tyr783 amino acid residue of Integrin β1 was shown to be 
dephosphorylated by PRL-3 both in vivo and in vitro (Tian et al., 2012). 
Additionally, other proteins, such as Integrin α1, Cadherin-22, Stathmin, FK506-binding 
protein 38 (FKBP38), Histone deacetylase 4 (HDAC4), ADP-ribosylation factor 1 (Arf1), 
Thioredoxin-related Protein 32 (TRP32), Repressor/Activator Protein 1 (RAP1), and 
Leo1, have also been demonstrated to interact with PRL-3 physically. However, whether 
PRL-3- shows any phosphatase activity towards these proteins is still unknown. Further 













Ezrin  Ezrin dephosphorylation HCT116 MS, PA (Forte et al., 2008) 
EF2  EF-2 dephosphorylation  HCT116 MS (Orsatti et al., 2009) 
KRT8  KRT8 dephosphorylation SW480 IP, MS 
(Mizuuchi et al., 
2009) 




HEK293 IP, PA 









IP, PD (Tian et al., 2012) 
 Integrin α1 N.D. COS-7 
IP, PD, 
Y2H 
(Peng et al., 2006) 
 Cadherin-22 
PRL-3 suppresses the 






(Liu et al., 2009) 
 Stathmin N.D. 
SW480, 
LoVo 
IP, MS  (Zheng et al., 2010) 
 FKBP38 
FKBP8 reduces the 
stability of PRL-3  
HeLa 
HEK293A 
IP, Y2H (Choi et al., 2011) 
 HDAC4 N.D. 
MOLM-14  
DLD-1 
IP (Zhou et al., 2011) 
 Arf1 PRL-3 activates Arf1  HeLa IP, PD (Krndija et al., 2012) 
 TRP32 
TRP32 reduces oxidized 
PRL-3  
HEK293 PD (Ishii et al., 2013) 
 RAP1 
PRL-3 induces cytosolic 
localization of RAP1 
HCT116 
BGC823 
IP, PD (Lian et al., 2013) 
 Leo1 
PRL-3 induces expression 
of Leo1 
SW480 IP, PD (Chong et al., 2014) 
MS, mass spectrometry; PA, phosphatase activity assays; IP, immunoprecipitation; PD, GST pull-down; Y2H, 
yeast 2-hybrid assay; N.D, not determined. 
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1.6 PRL-3-based cancer therapy 
Due to a critical role of PRL-3 in tumour progression, it has long been considered a 
potential target for cancer therapy, attracting the attention of many scientists in the past 
few years. To date, different groups are focusing on two major methods of PRL-3 
targeted therapy: PRL-3-based chemotherapy and PRL-3-based immunotherapy. 
1.6.1 PRL-3-based chemotherapy 
Chemotherapy is the use of drugs to suppress cancer cells by inhibiting cell growth and 
division (Liu et al., 2015). As PRL-3 is involved in cancer progression, several small 
molecule inhibitors of PRL-3 have been screened and identified that block PRL-3 activity 
in cells. Pentamidine, an anti-protozoan drug for leishmaniasis treatment, was the first 
reported inhibitor of PRL-3. It can block PRL-3 activity as well as the in vitro growth of 
PRL-3-positive human cancer cells. Besides PRL-3, Pentamidine could also inhibit 
several other PTPs, including PTP1B, mitogen-activated protein kinase (MAPK) 
phosphatase-1 (MKP-1), PRL-1, and PRL-2. Therefore, it remains elusive whether the 
suppression of cell growth is due to the specific inhibition of PRL-3 or a general inhibition 
of all these phosphatases (Pathak et al., 2002).  
Subsequently, it was found that some natural chemicals from plants, such as 
bioflavonoids, anthraquinones, and curcumin, could also act as PRL-3 inhibitors (Choi et 
al., 2006; Moon et al., 2010; Wang et al., 2009). Two bioflavonoids, ginkgetin and 
sciadopitysin, which are extracted from Taxus cuspidate, are the first known natural 
inhibitors of PRL-3 to be discovered. Similar to pentamidine, they strongly inhibit all 
three PRL members (Choi et al., 2006). Certain anthraquinones, such as emodin, were 
also shown to effectively block PRL-3 phosphatase activity, leading to an inhibition in 
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PRL-3-induced cancer cell migration and invasion (Han et al., 2012). Another natural 
inhibitor of PRL-3, curcumin, a polyphenol derived from the spice turmeric, was shown 
to selectively suppress PRL-3 expression and reduce PRL-3-mediated cell proliferation, 
migration and adhesion (Wang et al., 2009). 
Furthermore, modern high throughput screenings of chemical libraries have identified 
rhodanine derivatives as PRL-3 inhibitors (Ahn et al., 2006). Two of these derivatives, 
BR-1 and G-707, selectively inhibit PRL-3 phosphatase activity without affecting the 
activity of the other 10 PTPs. Moreover, they exhibit anti-tumour activity in both cell 
culture models and mouse xenograft models (Min et al., 2013). These findings have 
encouraged scientists to screen for other rhodanine derivatives as inhibitors of PRL-3. 
Recently, 12 novel potent inhibitors of PRL-3 were identified by structure-based virtual 
screening and in vitro enzymatic assays (Park et al., 2008). Some of these 12 lead 
compounds are rhodanine derivatives. However, in spite of a promising activity profile of 
the rhodanine derivatives, additional screening of these compounds is required for 
identification of true lead candidates. 
At present, thienopyridone (7-amino-2-phenyl-5H-thieno[3,2-c]pyridin-4-one) might be 
the most promising inhibitor of PRL-3 as it is the most characterized. It selectively 
inhibits PRLs, but not 11 other known PTPs (Daouti et al., 2008). Inhibition of PRLs by 
thienopyridone resulted in significant suppression of tumour cell anchorage-independent 
growth, anoikis, and an inhibition in cell migration through p130Cas cleavage (Daouti et 
al., 2008). 
Despite the recent successes in the identification of new PRL-3 inhibitors, the specificity, 
stability and solubility of these compounds could be improved further. In addition, since 
chemical compounds could have potential adverse side effects and toxicity, further 
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investigation of these drugs would be required before PRL-3-targeted inhibitors could be 
used in clinical cancer therapy. 
1.6.2 PRL-3-based immunotherapy 
Immunotherapy is a form of treatment that employs or enhances the function of the 
immune system to eliminate cancer cells. Normally, the immune system would detect and 
destroy abnormal cells to prevent disease occurrence. However, some cancer cells are 
able to avoid immune detection and destruction by undergoing mutations that help them 
escape immune surveillance, thus making it harder for the immune system to recognize 
and kill them. Hence, one approach to circumvent this problem is to mobilize the immune 
system by employing antibody-directed recognition of cancer cell makers to specifically 
target cancer cells. In comparison to chemotherapy, immunotherapy offers more 
specificity with less side effects (Makkouk and Weiner, 2015) . 
As discussed earlier, PRL-3 is a prenylated protein localized to the intracellular portion of 
the cell membrane. Based on this fact, it does not seem a promising candidate for 
antibody-directed cancer therapy as traditional dogma dictates that the cell membrane 
serves as a barrier to prevent antibodies from entering cells and therefore antibodies 
could only target external surface makers (Baker, 2005). However, an increasing body of 
evidence show that antibodies could enter cells and bind to intracellular antigens, leading 
to apoptosis (Hazin et al., 2015). Our lab was the first to demonstrate that anti-PRL-3 
monoclonal antibodies could dramatically reduce PRL-3-expressing metastatic lung 
tumour growth in nude mouse (Guo et al., 2008). Furthermore, a monoclonal antibody 
directed against PRL-1 also exhibited a strong inhibitory effect towards 
PRL-1-expressing metastatic lung tumours in nude mice. Notably, although both PRL-1 
and PRL-3 share significant amino acid sequence identity, PRL-3 monoclonal antibody 
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could not inhibit PRL-1 metastatic tumours. Similarly, PRL-1 monoclonal antibody 
specifically inhibited only PRL-1 but not PRL-3 metastatic tumours, suggesting a high 
specificity for antibody therapy against PRLs (Guo et al., 2008). In another experiment, 
mice primed for PRL-3 antibody production exhibited reduced metastatic tumour 
formation when injected with cancer cells in comparison to the unimmunized control 
mice (Guo et al., 2011). Moreover, chimeric monoclonal antibody directed against PRL-3 
also selectively inhibited the formation of PRL-3-expressing metastatic tumours, 
implying that cancer therapy targeting intracellular proteins with antibodies is feasible 
(Guo et al., 2012). 
However, the mechanism(s) behind this antibody targeted therapy is still largely 
unknown. A role for B-cells has been speculated for an effective immune response to 
PRL-3, as no therapeutic effect of PRL-3 antibody treatment was observed in B-cell 
deficient mouse models (Guo et al., 2012). Hence, further study of the mechanism is 
warranted to refine our understanding of PRL-3 based immunotherapy. 
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2.1. Reagents and antibodies 
2.1.1 Reagents 
The chemicals used in this study were as follows: Rapamycin (100 nM final; LC 
Laboratories, #R-5000); Akt Inhibitor VIII (5 μM; Santa Cruz Biotechnology, 
#sc-202048), U0126 monoethanolate (U0126) (10 μM, Sigma-Aldrich, #U120); 
bafilomycin A1 (50 nM; Sigma-Aldrich, #B1793), LY29400 (10 μM, Cell Signaling 
Technologies, #9901), PP2 (10 μM, Sigma-Aldrich, #P0042), Tyrphostin AG 490 (10 
μM, Sigma-Aldrich, #UT3434), SB203580 (10 μM, Sigma-Aldrich, #S8307), SP600125 
(10 μM, Sigma-Aldrich, #S5567), Cobalt(II) chloride (CoCl2) (5 μM, Sigma-Aldrich, 
#U60818) 
2.1.2 Antibodies 
The Antibodies used in this study were obtained as indicated in the following: Antibodies 
against mTOR (#2983), p-mTOR S2448 (#2971), 4E-BP1 (#9644), p-4E-BP1 T37/46 
(#2855), p-p70S6K T389 (#9234), TSC2 (#4308), and p-TSC2 S939 (#3615), Erk1/2 
(#4695), p-Erk1/2 (#4370), AMPKα (#2603), p-AMPKα T172 (#2535), Akt (#4691), 
p-Akt S473 (#4060), raptor (#2280), p-JNK (#9251), JNK (#9252), p-p38 MAPK 
(#4511), p38 MAPK (#9212), Cleaved PARP (#9544), ASK1 (#8662), p-ASK1 T845 
(#3765), MKK4 (#9152), p-MKK4 S257 (#4514), p-MKK4 T261 (#9151), MKK3 
(#8535), p-MKK3/6 (#9236) were purchased from Cell Signaling Technologies (Danvers, 
MA, USA). Anti-p70S6K (#611260) antibody was purchased from BD Biosciences (San 
Jose, CA, USA). Anti-LAMP2 (#ab25631) antibody was purchased from Abcam 
(Cambridge, England, UK). Antibodies against GST (#sc-138) and GFP (#sc-9996) were 
purchased from Santa Cruz Biotechnology (Dallas, TX, USA). HRP-conjugated sheep 
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anti-mouse (#515-035-062) and goat anti-rabbit (#111-035-045) antibodies were 
purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA), 
whilst AlexaFluor568-conjugated goat anti-mouse (#A-11004) and 
AlexaFluor633-conjugated goat anti-rabbit (#A-21071) antibodies were from Life 
Technologies (Grand Island, NY, USA). Anti-PRL3 antibody was generated by our own 
lab previously (Li et al., 2005). 
2.2. Plasmids and siRNA 
2.2.1 Plasmids 
The pEGFP-PRL-3 and catalytically-inactive pEGFP-PRL-3-C104S constructs were 
generated by our own lab previously (Wang et al., 2007a). The 
pRK5-HA-GST-RagB-WT (#19301), pRK5-HA-GST-RagC-WT (#19304), 
pRK5-HA-GST-RagD-WT (#19307), pRK5-HA GST RagB 54L (#19302), and 
pRK5-HA GST RagD 121L (#19309) constructs were gifts from David Sabatini and 
sourced from Addgene (Cambridge, MA, USA). The pCDNA3-Flag-p38a construct was 
a gift from Roger Davis and sourced from Addgene (# 20352). Human PRL-3-targeting 
shRNA (5’-TTCTCGGCACCTTAAATTATT-3’) have been reported previously 
(Al-Aidaroos et al., 2013). Expression vectors encoding PRL-3–directed 
(5′-TTCTCGGCACCTTAAATTATT-3′) or non-targeting scrambled shRNA sequences 
were purchased from OriGene (Rockville, MD, USA).  
2.2.2 siRNA 
Human AKT-targeting (# 6211) and control siRNA (# 6568) were purchased from 
Cell Signaling Technologies. 
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2.3. Cell lines and derivatives 
2.3.1. Cell lines 
Human colon cancer cell lines (HCT116, HCT15, LoVo, SW620, DLD-1), human 
cervical cancer cells (HeLa), human melanoma cells (G361), and human breast cancer 
cells (MCF7) were purchased from ATCC (Manassas, VA, USA). Human ovarian cancer 
cells (A2780) were purchased from ECACC (Salisbury, England, United Kingdom).  
2.3.2. Generation of stable cancer cell lines with expression of EGFP, 
EGFP-PRL-3 or EGFP-PRL-3-C104S 
HCT116, DLD-1 and MCF-7 cells were seeded in their respective antibiotic-free media 
in a 12-well culture plate (1 x 10
5
 cells/well). Lipofectamine2000, a cationic lipid-based 
transfection reagent (Invitrogen, USA), was used according to manufacturer’s protocol. 1 
µg of pEGFP-C1, pEGFP-PRL-3 or pEGFP-PRL-3-C104S plasmid DNA were mixed 
with 2 µL Lipofectamine2000 and diluted in 200 µL OptiMEM media for 20 min before 
transfecting cells, to form DNA-lipid complexes. Then, the DNA-lipid complexes were 
added evenly over the cells. After overnight incubation, cells were reseeded to a 150 mm 
tissue culture dish with their respective growth media supplemented with 1 mg/mL 
neomycin. And the selection sustained for 2 weeks to obtain cell populations with at least 
90% GFP positivity. The GFP signal was confirmed using an Eclipse TE2000-U inverted 
fluorescence microscope (Nikon, Japan). While all the mock-transfected cells were died 
after 2 weeks of neomycin selection. Stable cell pools were thereafter grown in normal 
complete media without neomycin selection. Early passage stocks were kept in growth 
media supplemented with additional FBS (20% v/v final) and DMSO (10% v/v) and 
stored in -80°C or liquid nitrogen. 
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2.3.3. Generation of HCT116 cancer cell lines with stable PRL-3 knockdown 
SureSilencing shRNA plasmids (Origene, USA) encoding either a non-targeting 
scrambled or human PRL-3-targeting shRNA (5’-TTCTCGGCACCTTAAATTATT-3’) 
were transfected as described above in HCT116 cells. After 2 weeks of puromycin 
selection (1 μg/mL), individual colonies were picked and expanded. And the cells 
showing ≥75% knockdown of PRL-3 expression were stored and used for subsequent 
experiments. Viable cells were not found in mock-transfected cells after 2 weeks of 
puromycin selection. 
2.3.4. Cell culture and Treatments 
Cells were grown in RPMI-1640 media supplemented with 10% FBS (HyClone, 
Carlsbad, CA, USA) and 1% (v/v) penicillin/streptomycin in a humidified incubator at 
37°C with 5% CO2. For serum depletion (serum-free; SF) experiments, cells were washed 
twice in PBS and changed to RPMI-1640 media without FBS, supplemented with 1% 
(v/v) penicillin/streptomycin. For hypoxia experiments, cells were placed in a GasPak EZ 
Gas Pouch (BD Biosciences, Sparks, MD, USA) containing ≤ 1% O2. For amino acid 
starvation (AA-) experiments, cells were washed twice in PBS, once with Earle’s 
Balanced Salt Solution (EBSS), and finally incubated with EBSS media without FBS for 
1 h. For conditioned media analysis, cells were washed thrice in PBS and cultured in 
RPMI-1640 media without FBS for 24 h. Then media was collected and condensed using 
centrifugal concentrators. Where indicated, cells were treated with rapamycin (100 nM 
final; LC Laboratories, #R-5000), Akt Inhibitor VIII (5 μM final; Santa Cruz 
Biotechnology, #sc-202048), U0126 monoethanolate (U0126) (10 μM, Sigma-Aldrich, 
#U120); bafilomycin A1 (50 nM; Sigma-Aldrich, #B1793), LY29400 (10 μM, Cell 
Signaling Technologies, #9901), PP2 (10 μM, Sigma-Aldrich, #P0042), Tyrphostin AG 
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490 (10 μM, Sigma-Aldrich, #UT3434), SB203580 (10 μM, Sigma-Aldrich, #S8307), 
SP600125 (10 μM, Sigma-Aldrich, #S5567), Cobalt(II) chloride (CoCl2) (2 μM - 10 μM, 
Sigma-Aldrich, #U60818), or DMSO alone (0.1% final). 
2.3.5. Transit Small-interfering RNA (siRNA) and plasmids transfection 
For siRNA, human AKT-targeting (catalogue number 6211S) and control siRNA were 
from Cell Signaling Technologies. siRNA (100 nM final) was transiently transfected 
using jetPRIME (Polyplus-transfection SA, Illkirch, France) following the 
manufacturer’s recommended protocol. Briefly, cells cultured in 6-well plate were 
transfected with the siRNA for 48 h, then subjected to the designated treatments. For 
plasmids transfection, the plasmids were also transfected using jetPRIME reagents. After 
24 h transfection, cells were subjected to following treatments. 
2.4. RNA extraction 
The RNeasy kit (Qiagen, USA) was utilized for cellular RNA extraction according to the 
manufacturer’s protocol. Briefly, sub-confluent cell monolayers cultured in 6-well plates 
(~80%; 1x10
6 
cells) were harvested, washed by PBS, and lysed in 350 µL of Buffer RLT 
containing 1% β-mercaptoethanol (v/v). Then, the lysates were passed through a 
QIAshredder spin column once (Qiagen, USA) to homogenize cells. 350 µL of 70% 
ethanol (v/v) was subsequently mixed with homogenates, and transferred into an RNeasy 
spin column. After the initial spin, the column containing membrane-bound RNA was 
washed once with 700 µL Buffer RW1, twice with 500 µL Buffer RPE, and spun 
completely dry. 30 µL of RNase-free water was used for RNA elution. Purified RNA was 
analyzed and quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific). 
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2.5. Semi-quantitative (RT-PCR) 
SuperScript III First Strand Synthesis System (Invitrogen, USA) were used for reverse 
transcription according to manufacturer’s protocol. Then, for RT-PCR, HotStarTaq 
Master Mix Kit (QIAGEN, USA) was utilized following manufacturer’s protocol. The 
primer set sequences used are as follows: human β-actin forward (5’-TCA CTC ATG 
AAG ATC CTC-3'), human β-actin reverse (5’-TTC GTG GAT GCC ACA GGA C-3'), 
human MMP2 forward (5’-CAC TTT CCT GGG CAA AT-3'), human MMP2 reverse 
(5’-TGA TGT CAT CCT GGG ACA GA-3'), human MMP9 forward (5’-GAG ACC 
GGT GAG CTG GAT AG-3'), human MMP9 reverse (5’-TAC ACG CGA GTG AAG 
GTG AG-3'). Then, PCR products were detected by agarose gel electrophoresis and 
imaged in a UV trans-illumination chamber equipped with a CCD camera.  
2.6. Immunoprecipitation 
All immunoprecipitation (IP) assays were performed in spin columns (Thermo Scientific, 
USA). Before IP assay, 20 µL equilibirated Protein-A/G beads were first bound to the 
designated antibodies (4 µL each) by 1 hour incubation with IP-Wash buffer (10 mM 
sodium phosphate, 150 mM NaCl; pH 7.2) at room temperature (RT) on an end-over-end 
rotator. Then, three volumes of IP-Wash Buffer were used to wash away the unbound 
antibodies (three times). For crosslinking, 450 µM disuccinimidyl suberate (DSS) was 
used to crosslink these antibodies to Protein-A/G beads in IP-Wash buffer for 45 min at 
RT. The termination of crosslinking reaction was performed by using two volumes of 
Elution buffer (0.1 M glycine; pH 2.8) to wash the antibody-bead conjugates twice, 
followed by four volumes of Lysis buffer (25 mM Tris, 150 mM NaCl, 1% NP-40, 
supplemented with a protease inhibitor cocktail and phosphatase inhibitor cocktail; pH 
7.3) twice.  
38 
 
For each IP reaction, cells cultured in 60 mm culture dishes were collected with 300 µL 
Lysis buffer. After a 10 min incubation (on ice), lysates were centrifuged for 10 min at 
16,000 x g at 4°C. Supernatants were collected, quantitated, and normalized to similar 
protein amounts. Then 30 µL supernatants were saved as an input control for each IP 
reaction. The antibody-bead conjugates described above were added to the remaining 
supernatants. After 16 h incubation at 4°C, immunoprecipitates were subsequently 
washed with Lysis buffer four times. Finally, 40 µL Elution buffer was used to collect 
immunoprecipitates. Lysates aliquots and eluted immunoprecipitates were stored at 
-80°C until use. 
2.7. Western Blotting 
Western blots were performed as described (Li et al., 2005). Briefly, cells were washed 
with ice-cold PBS and lysed in RIPA buffer containing a cocktail of EDTA-free protease 
inhibitors (Roche, Mannheim, Germany) and phosphatase inhibitors (Nacalai Tesque, 
Kyoto, Japan). Lysates were subjected to western blotting with indicated primary 
antibodies at 1:1,000 dilutions. Species-specific secondary antibodies were used at 
1:2,000 dilutions. Protein-antibody conjugates were visualized using a chemiluminescent 
detection kit (Thermo Scientific, Waltham, MA, USA), and quantification of band 
intensities was done using ImageJ software. The ratio of phosphorylated/total protein was 
calculated and normalized as described in the figure legends. 
2.8. Production of GST fusion proteins for cytosolic pull-down assays 
After expansion of glycerol stocks of BL21 E.coli cells carrying either pGST-KG or 
pGST-PRL-3 plasmids by incubating the cells in 3 mL LB-ampicillin overnight, all 3 mL 
of bacteria culture was transferred into 500 mL LB-ampicillin and incubated till an OD600 
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of ~0.6. Then, 0.25 mM IPTG were added for 3 h at 37°C. Bacteria cells were spun down 
and resuspended in Bac-Lysis buffer [20 mM Tris pH 7.5, 500 mM NaCl, 1 mg/mL 
lysozyme, 2 mM dithiothreitol (DTT), 2 mM benzamidine, 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF)]. The homogenization was performed on ice by 
using a sonicator (large tip; 1 min, 3 times) with 1 min cooling between pulses. Then 
after clarification of these resulting lysates by centrifugation, the pre-cleared glutathione 
sepharose beads (Amersham, USA) were added to clarified lysates and incubated for 3 h 
on a rotator at 4°C. Protein-bound beads were washed by Bac-Lysis buffer (trice), 
low-salt buffer (20 mM Tris pH 7.5, 200 mM NaCl, 2 mM DTT, 2 mM benzamidine, 0.1 
mM PMSF, twice), and immediately quantified and utilized for GST-pulldown assays.  
2.9. Immunoflurescence Analysis 
Immunofluorescence analysis was carried out as previously described (Li et al., 2005). 
Briefly, cells grown on glass coverslips were subjected to various treatments as indicated 
before rinsing with PBS and fixation for 15 min with 4% paraformaldehyde in PBS. After 
rinsing twice with PBS, cells were blocked for 1 h in 5% BSA blocking buffer containing 
0.1% Triton-X 100, and incubated with mouse anti-LAMP2 (1:100) and rabbit 
anti-mTOR (1:100) antibodies overnight at 4°C. Coverslips were then rinsed three times 
with PBS and subsequently incubated with secondary antibodies (1:200) for 1 h at RT 
followed by a further three washes in PBS. Coverslips were mounted on glass slides 
using DAPI-containing mounting media and analysed using an LSM700 confocal 
microscope (Carl Zeiss AG, Jena, Germany). 
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2.10. Cell MTS Assay 
For MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 
-2H-tetrazolium) assays, 2 x 10
3
 cells were seeded in 10% FBS media into triplicate wells 
of a 96-well plate and allowed to attach overnight. Then the cells were subjected to 
designated treatments, and left to incubate for 24 or 48 h. The media was subsequently 
aspirated, and replaced with 150 uL 0.5% FBS media containing MTS (Promega) and 
formazan development was done for 2 h at 37° at 5% CO2 before measuring absorbance 
at 490 nm (formazan product) and 630 nm (reference wavelength) in a 
spectrophotometer. 
2.11. Wound Healing Assay 
3.5 x 10
4
 HCT116-Vec or HCT116-PRL-3 cells were seeded into μ-dishes (Ibidi, 
Martinsried, Germany) and cultured under normal conditions until they reached 
confluence. Subsequently, inserts were removed to yield standardized 500 µm-wide gaps. 
‘Wounded’ cell monolayers were washed in PBS and subsequently cultured in low-serum 
media (0.5% FBS) with 100 nM rapamycin or 0.1% DMSO for 48 h. Images were 
acquired sequentially every 24 h using an Axiovert 200M inverted microscope (Carl 
Zeiss AG). 
2.12. Invasion assay 
1 x 10
4
 HCT116-EGFP or HCT116-EGFP-PRL-3 cells were suspended in complete 
media containing 100 nM rapamycin or 0.1% DMSO and seeded into BioCoat Matrigel 
invasion chambers with 8.0 μm PET membranes (Corning, MA, USA). After incubation 
for 24 h at 37°C, non-invading cells were removed from the upper surface of the 
membrane by a cotton swab, and membrane inserts were washed three times with PBS 
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and fixed in 4% paraformaldehyde for 15 min. Subsequently, membranes were cut, 
mounted inverted on glass slides, and observed for EGFP fluorescence under an LSM700 
confocal microscope (Carl Zeiss AG). The numbers of invaded cells in four 
ramdomly-chosen fields were counted. Data were presented as mean ± SE of cell 
number/field and statistically analyzed using the Student’s t-test. 
2.13. in vitro Rag GTPase binding assay 
GST-RagB and GST-RagC vectors were co-transfected into HCT116-EGFP or 
HCT116-EGFP-PRL-3 stable cells. The next day, culture media was replenished before 
placing cells under normoxia, hypoxia, or serum-free conditions for a further 24 h. 
Lysates were harvested, clarified by high speed centrifugation (14 000 × g, 15 min), and 
incubated with glutathione beads overnight at 4°C with rotation. The beads were washed 
three times with lysis buffer and finally eluted with reduced glutathione (25 mM). Elutes 
were subjected to western blotting with the indicated antibodies.  
2.14. Analysis of human gastric tissues 
Human gastric tissue samples were obtained with patient consent from the National 
University Hospital-National University of Singapore (NUH-NUS) Tissue Repository. 
Experimental procedures were approved by the Institutional Review Board (IRB) of 
NUH-NUS for research use and conducted in accordance with approved guidelines and 
regulations. 
2.15. Analysis of mouse mammary tissues 
For the isolation of mammary tissue lysates, the uppermost pair of mammary glands from 
wild-type FVB/N mice or MMTV-PyMT mice (at 6, 9, 12, and 15 weeks)  were 
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surgically removed, rinsed in PBS, and homogenised in RIPA lysis buffer using a 
Polytron homogenizer (Luzern) prior to western blot analysis. All animal studies were 
approved by an Institutional Animal Care and Use Committee (IACUC) and were 
performed in accordance with approved guidelines and regulations of the Biological 
Resource Centre, A*STAR, Singapore. 
2.16. In vitro malachite green phosphate assay 
The in-vitro malachite green phosphate assay was performed by using Malachite Green 
Phosphate Assay Kit (Bioassay systems, #POMG-25H) following the manufacturer’s 
protocol. Briefly, working reagent was prepared by mixing 100 vol of Reagent A and 1 
vol of Reagent B at RT. Then 20 µL of working reagent was incubated with 80 µL of the 
sample solution containing GST-PRL-3 and Flag-p38, GST-PRL-3 and Flag-ctrl, 
GST-Ctrl and Flag-p38, or GST-Ctrl and Flag-Ctrl proteins in a 96-well plate for 30 min 
at RT for color development. The absorbance at 600 nm - 660nm (620 nm) were 
measured by a plate reader (BD Biosciences, USA). The phosphate standard curve was 
also established by following the same protocol above (1 mM phosphate was provided in 
the kit) at the same time. Finally, the amount of free phosphate was analyzed and 
determined by using Excel software (Microsoft, USA). 
2.17. Detection of Reactive Oxygen Species (ROS) 
The ROS level was detected by CM-H2DCFDA (Thermo Fisher Scientific, #C6827). 
Briefly, cells were cultured in 24-well plate, and followed with the designated treatments. 
Then after incubation with PBS containing 10 μM CM-H2DCFDA for 10 min, cells were 
trypsinized, washed, and examined by fluorescence microscope (Nikon) or BD FACS 
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cytometer (BD Biosciences). The quantitative data were presented as Means±SE and 
analysed using Student's t test. 
2.18. Rheb activation assay 
Analysis of intracellular Rheb-GTP levels was done using a Rheb activation assay kit 
(Abcam), according to the manufacturer’s instructions. Briefly, 2.5 × 106 cells, grown 
under the indicated culture conditions, were washed with ice-cold PBS and lysed in 
kit-supplied lysis buffer containing a cocktail of EDTA-free protease inhibitors (Roche). 
Lysates were clarified by centrifugation (16,000 ×  g, 10 min) before equivalent 
amounts of lysates (2 mg) were subjected to immunoprecipitation with a 
configuration-specific monoclonal antibody that specifically recognizes RheB-GTP, but 
not RheB-GDP. Western blotting and densitometry analysis was subsequently used to 
characterize the proportion of active Rheb (as reflected by the Rheb-GTP/Rheb ratio) 
present in cellular extracts. 
2.19. Statistical Analysis 
For the proliferation assays, the Student’s t-test was used to test for significant 
differences. Statistical analyses of the colon cancer patient dataset GSE40967 (n = 566) 
were performed using SPSS 19.0 software (IBM, NY, USA). Correlation between PRL-3 
and MMP-2, MMP-7, or MMP-9 gene expression was analysed by Spearman Correlation. 
The association between PRL-3 expression and relapse-free survival (RFS) was analysed 
by Kaplan-Meier analysis. p values < 0.05 were considered statistically significant. All 




3. PRL-3 ACTIVATES mTOR SIGNALLING  






The mechanistic target of rapamycin (mTOR) is a critical regulator of cell growth and 
homeostasis (Laplante and Sabatini, 2012). It senses and integrates a variety of signals 
from growth factors, nutrients, and environmental stressors to regulate many biological 
processes, such as mRNA translation, protein synthesis, metabolism, proliferation, 
autophagy, cell survival, and cytoskeletal organization (Sarbassov et al., 2005a). 
mTOR was first discovered from studies on the action of the macrolide, rapamycin, in the 
early 1990s (Brown et al., 1994; Chiu et al., 1994; Sabatini et al., 1994; Sabers et al., 
1995). It is an evolutionarily conserved atypical serine/threonine protein kinase,  
particularly in mammals, where it shares a remarkable 95% amino acid sequence identity 
(Janus et al., 2005). Full-length mTOR has a molecular weight of 289 kDa, and consists 
of multiple functional motifs (Figure 3.1), including two focal adhesion targeting (FAT) 
domains, a FKPB12-rapamycin binding (FRB) domain,  a catalytic kinase (KIN) 
domain at the C-terminus, and up to 20 tandem repeated motifs at the N-terminus (known 
as HEAT repeats) (Hoeffer and Klann, 2010; Yip et al., 2010). The FAT domains are 
essential for mTOR catalytic activity and are highly homologous to the lipid kinase 
domain of PI3K, thus grouping mTOR as a member of the large PI3K-related kinase 
(PIKK) family. The FRB domain and HEAT repeats are regions where mTOR binds to 
other proteins. The KIN domain contains several evolutionarily conserved serine and 
threonine residues, which can regulate mTOR activity via phosphorylation (Hoeffer and 
Klann, 2010; Jacinto, 2008). Of particular note is the Ser2448 residue, whose 
phosphorylation level correlates with mTOR catalytic activity (Chiang and Abraham, 




Figure 3.1 mTOR primary structure. Key motifs have been marked. 
In cells, mTOR exists as components of large, heteromeric protein complexes, with 
differing biological functions (Laplante and Sabatini, 2012). At present, two complexes 
have been identified, namely mTOR complex 1 (mTORC1), and mTOR complex 2 
(mTORC2). mTORC1 comprises six known subunits, while mTORC2 comprises seven 
known subunits (Figure 3.2). Both complexes share some common subunits, including 
mTOR, GβL (also known as mLST8) (Kim et al., 2003), Deptor (Peterson et al., 2009), 
and the Tti1/Tel2 complex (Kaizuka et al., 2010).  mTORC1 also contains its own 
unique subunits: Raptor (Hara et al., 2002; Kim et al., 2002) and PRAS40 (Sancak et al., 
2007; Thedieck et al., 2007; Wang et al., 2007b), while mTORC2-specific components 
include Rictor (Jacinto et al., 2004; Sarbassov et al., 2004), Protor1/2 (Pearce et al., 2007), 
and mSin1 (Frias et al., 2006). Of these differences, Raptor and Rictor are classically 
used to distinguish between mTORC1 and mTORC2, respectively. Interestingly, 
mTORC1 and mTORC2 exhibit different sensitivities to rapamycin. Unlike mTORC1, 
mTORC2 does not bind to rapamycin and is much less sensitive to rapamycin treatment 
(Jacinto et al., 2004; Sarbassov et al., 2004). In these complexes, besides the catalytic 
core subunit mTOR, other components are also critical to the regulation of mTOR 
complex activity, functioning as either positive or negative regulators, although their 




Figure 3. 2 Components of mTORC1 and mTORC2.  
Given their unique compositions, mTOR complexes also have their distinct functions. 
mTORC1 mainly regulates protein synthesis, lipid biogenesis, mitochondrial metabolism, 
cell growth, and autophagy (Zoncu et al., 2011). It has two well-known, direct, 
downstream targets: eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 
(4E-BP1), and p70 S6 kinase (p70S6K), both of which function as translational regulators 
(Ma and Blenis, 2009). The phosphorylation of 4E-BP1 blocks its inhibitory effect on 
eIF4E, allowing for m7GTP cap-dependent translation to proceed, whereas p70S6K 
phosphorylation promotes the formation of translation initiation complexes enhancing 
mRNA translation and thus modulating protein synthesis (Kantidakis et al., 2010). In 
contrast to mTORC1, much less is known on mTORC2 downstream pathways. It is 
thought that mTORC2 can regulate anabolism, cell survival, and cytoskeletal 
organization via phosphorylation of Akt and PKCα (Ikenoue et al., 2008; Oh and Jacinto, 
2011; Sarbassov et al., 2005b; Zhang et al., 2012a). 
Dysregulation of mTOR signalling occurs in many human diseases (Dazert and Hall, 
2011; Laplante and Sabatini, 2012). One example is in cancer, where mTORC1 
signalling is frequently hyper-activated (Depowski et al., 2001; Kirkegaard et al., 2005). 
Recent reports show that up to 80% of human cancers display hyper-activation of 
mTORC1 signalling due to loss of tumour suppressors or activation of oncogenes 
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(Cargnello et al., 2015). This constitutive mTORC1 activation is thought to trigger cancer 
development and progression by enhancing the synthesis of oncogenic proteins that 
regulate proliferation, energy metabolism, cell survival, cell motility, angiogenesis, and 
metastasis (Laplante and Sabatini, 2012; Zhou and Huang, 2010). 
PRL-3 has previously been reported as a metastasis-associated oncoprotein, whose 
expression positively correlates with advanced cancer stages (Bessette et al., 2008; Saha 
et al., 2001). Analysis of cancer patient samples revealed a high frequency of PRL-3 
expression in many types of tumours but not in paired normal tissues, highlighting the 
significance of PRL-3 as a marker of poor prognosis in multiple cancer types (Bessette et 
al., 2008; Park et al., 2013a; Wang et al., 2010). An understanding of the molecular roles 
of PRL-3 has thus emerged as a new frontier in cancer research.  
Interestingly, like mTORC1, PRL-3 has been shown to promote tumour initiation and 
progression through various means, including accelerating cell proliferation, preventing 
cell death, inducing angiogenesis, as well as enhancing cell invasion and metastasis 
(Al-Aidaroos and Zeng, 2010). Based on this observation, it was hypothesized that 
PRL-3 might induce cancer progression by potentially regulating mTOR signalling. To 
test this hypothesis, the following objectives will be addressed: 
i) To test whether PRL-3 could activate mTOR signalling; and 




3.2. Experimental outline 
1. Determine the relevance of PRL-3 expression and mTOR activation in vivo and in 
vitro. 
2. Investigate the effect of PRL-3 overexpression on mTOR signalling under both 
normal and stressed conditions. 
3. Study the biological effect of PRL-3-mediated activation of mTOR signalling under 
rapamycin treatment. 
4. Analyse the colon cancer patient cohorts to elucidate the clinical relevance of the 




3.3.1. PRL-3 expression positively correlates with mTOR activity in vivo 
To investigate the relationship between PRL-3 expression and mTOR activity, 12 sets of 
tumours and matched normal tissue samples from gastric cancer patients were analysed 
for protein expression levels of PRL-3 and phosphorylation status of Thr37/46 on 
4E-BP1, a direct mTORC1 substrate and an indicator of mTOR oncogenic activity 
(Brunn et al., 1997). PRL-3 protein was found to be exclusively expressed in all tumour 
samples, but not in any of the patient-matched normal samples (Figure 3.3A). Notably, 
phosphorylated 4E-BP1 also exhibited a distinct expression pattern between tumours and 
their matched normal tissues samples. Subsequently, using the software Image J, the 
densitometric ratio of phosphorylated 4E-BP1/total 4E-BP1 for each sample was 
quantified and the fold changes between each tumour and paired normal sample were 
compared. It was found that 9 out of 12 (75%) PRL-3-expressing tumours showed higher 
ratios of phosphorylated 4E-BP1/total 4E-BP1 than their matched normal tissue samples 
(asterisks, Figure 3.3B). These clinical results imply a possible relationship between 
PRL-3 expression levels and mTOR activity in tumour tissues. 
To determine whether changes in PRL-3 expression correlates with mTOR activity in 
vivo, spontaneous mouse mammary tumour virus (MMTV) transgenic models were 
employed.  This model expresses a polyomavirus middle T oncoprotein (PyMT) under 
the transcriptional control of a MMTV promoter-enhancer, leading to the formation of 
palpable mammary tumours in female mice as early as 6 weeks old (Guy et al., 1992). In 
the MMTV-PyMT system, PyMT was highly expressed in mammary tissues at relatively 
constant levels in heterozygous transgenic adult female mice (Figure 3.3C). In contrast, 
endogenous PRL-3 protein expression increased steadily over the same period, 
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accumulating at later stages of tumour development (Figure 3.3C). Significantly, the 
increase in PRL-3 expression during mammary tumour development closely correlated 
with an increase in levels of both phosphorylated 4E-BP1 and phosphorylated Ser2448 of 
mTOR, but not protein expression levels of either (Figure 3.3C). Importantly, Ser2448 of 
mTOR lies within the C-terminal ‘repressor domain’ of mTOR, and its phosphorylation 
is an important marker for activation of the mTOR/4E-BP1 pathway (Chiang and 
Abraham, 2005; Sekulic et al., 2000). 
In conclusion, these in vivo observations suggest that I) a correlation between PRL-3 
expression levels, mTOR activity, and mTOR activation-associated phosphorylation 
exists, and II) PRL-3 might regulate mTOR activity by post-translational modification(s) 




Figure 3. 3 PRL-3 expression positively correlates with mTOR activity in vivo.  
(A) Twelve pairs of tumour and matched normal tissues from gastric cancer patients were 
analysed with antibodies against PRL-3, p-4E-BP1 (T37/T46), total 4E-BP1, and 
GAPDH. (B) The ratio of phosphorylated/total 4E-BP1 band densities in tumour tissues 
were calculated and normalized to the phosphorylated/total 4E-BP1 ratio in matched 
normal tissues. Asterisks, patient tumour samples wherein 4E-BP1 hyperphosphorylation 
correlates with PRL-3 expression. (C) Normal and MMTV-PyMT mammary tissues over 
the course of spontaneous tumour development (6, 9, 12, and 15 weeks) were analyzed 
with antibodies against PyMT, PRL-3, p-4E-BP1 (T37/46), 4E-BP1, p-mTOR (S2448), 
mTOR and GAPDH. Top panel, images of normal mice (N) or transgenic MMTV-PyMT 
mice (T) between the ages of 6 to 15 weeks. Middle panel, representative images of 
excised breast tissues from mice. Blue dashed lines, gross size of palpable mammary 
tumours in MMTV-PyMT mice. Lower panels, correlation between PRL-3 expression 
and phosphorylation of 4E-BP1 and mTOR. 
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3.3.2. PRL-3 induces mTOR phospho-activation in vitro 
Previously, in ovarian cancer, PRL-3 was shown to promote autophagy (Huang et al., 
2014), which is a self-degradative process inhibited by mTOR activity (Jung et al., 2010). 
To clarify the apparent discordance between the activation of both mTOR and autophagy 
by PRL-3, plasmids encoding EGFP-PRL-3 (PRL-3), EGFP-PRL-3-C104S (C104S; 
catalytically-inactive mutant), or empty EGFP vector (Vec) were transiently transfected 
to nine different human cancer cell lines from diverse tissue types. In six out of the nine 
cell lines tested (67%), consistent 1.4-2.5 fold increase in mTOR phosphorylation was 
observed upon overexpression of wild-type PRL-3, but not the catalytic-inactive PRL-3 
mutant or vector control (Figure 3.4A). However, in three out of nine cell lines (33%), 
no increase in mTOR phosphorylation was observed upon PRL-3 expression (Figure 
3.4B). Notably, this latter group included A2780 human ovarian cancer cells, wherein 
PRL-3 was previously reported to activate autophagy (Huang et al., 2014). Interestingly, 
rapamycin-mediated inhibition of mTOR failed to dampen the increase in autophagy 
promoted by PRL-3 in A2780 cells (Huang et al., 2014), indicating an 
mTOR-independent route of autophagy activation by PRL-3 in these cells. Taken 
together, these results suggest that PRL-3 overexpression results in mTOR 




Figure 3. 4 PRL-3 induces mTOR phospho-activation in vitro. Overexpression of 
EGFP vector (Vec), EGFP- PRL-3 (PRL-3) or EGFP-PRL-3-C104S (C104S) in a panel of 
9 human cancer cell lines. PRL-3 upregulates mTOR phosphorylation in (A) HCT116, 
HeLa, MCF7, HCT15, LOVO, and SW620 cells, but not in (B) G361, DLD1 or A2780 
cells. GAPDH served as a loading control. For each cell line, the ratio of 
phosphorylated/total mTOR band densities were calculated and normalized to the 
phosphorylated/total mTOR ratio in corresponding vector control lanes. 
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3.3.3. PRL-3 activates mTOR signalling under both normal and stressed 
conditions 
As discussed earlier, the mTOR pathway integrates multiple environmental cues to 
regulate translation in response to stress. Deprivation of oxygen or nutrients, particularly 
amino acids, results in reduced mTOR activation and dephosphorylation of downstream 
effectors of protein translation, including 4E-BP1 and p70S6K (Arsham et al., 2003; 
Proud, 2002). To investigate whether PRL-3-mediated hyperactivation of mTOR could 
persist under such stressors, HCT116 cells stably expressing EGFP-PRL-3 (PRL-3), 
EGFP-PRL-3-C104S (C104S; catalytically-inactive mutant), or empty EGFP vector 
(Vec), were engineered and cultured under normal, hypoxia (oxygen-deprived), serum 
free, or amino-acid starved conditions to monitor mTOR activity. Hypoxia, serum 
deprivation, and amino acid starvation are three well-characterized environmental 
stressors that inhibit mTOR activity (Bai and Jiang, 2010; Demetriades et al., 2014). 
Interestingly, despite a reduction in mTOR phosphorylation in cells grown under these 
stress conditions, HCT116-PRL-3 cells displayed persistent hyperphosphorylation of 
mTOR relative to HCT116-Vec or HCT116-C104S cells (Figure 3.5A, lanes 2, 5, 8, 11, 
14). Moreover, a similar trend in the phosphorylation status of mTOR’s direct 
downstream effector-substrates – 4E-BP1 and p70S6K – was also observed. In 
particularly, the phosphorylation level of 4E-BP1 and p70S6K in HCT116-Vec and 
HCT116-C104S cells were reduced drastically under hypoxia and amino-acid starved 
conditions, yet HCT116-PRL-3 cells maintained a high phosphorylation level of these 
two substrates, indicting persistent activation of mTOR signalling (Figure 3.5A). 
To discount the possibility of a cell-specific observation, similar experiments were 
carried out in HeLa cells. Similar results were obtained in this cell line, wherein cells 
overexpressing PRL-3 persistently promoted mTOR hyperphosphorylation and 
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downstream signalling relative to cells overexpressing control (Vec) or 
catalytically-inactive PRL-3 mutant (C104S) (Figure 3.5B).  
In a complimentary approach, small hairpin RNA (shRNA) constructs were used to 
stably deplete PRL-3 from HCT116 cells which express endogenous PRL-3 abundantly. 
In contrast to PRL-3 overexpression, depletion of PRL-3 in HCT116 cells resulted in 
reduced phosphorylation of mTOR and its downstream effectors 4E-BP1 and p70S6K 
under normal, hypoxia, serum free, and amino-acid starved conditions (Figure 3.5C). 
Thus, these results suggest that PRL-3 activates mTOR signalling under both normal and 







Figure 3. 5 PRL-3 activates mTOR signalling under both normal and stressed 
conditions. (A) HCT116-Vec, HCT116-PRL-3 and HCT116-C104S cells were cultured 
for 24 h in full media under normal (Ctrl), hypoxia (Hx), or serum free (SF) conditions, or 
cultured for 1 h in full media under normal (Ctrl) or amino-acid starved (AA-) conditions. 
Then cells were lysed and western blot analysis was performed with antibodies against 
PRL-3, p-mTOR (S2448), mTOR, p70-S6K, p-p70-S6K (T389), 4E-BP1, p-4E-BP1 
(T37/T46) and GAPDH. GAPDH used as a loading control. (B) HeLa cells were 
transfected with EGFP-PRL-3 (PRL-3), EGFP-PRL-3-C104S, or empty EGFP vector 
(Vec), then cells were cultured and analysed as in (A). (C) HCT116 cells stably expressing 
small hairpin RNA (shRNA) against PRL-3 (shPRL-3) or control shRNA (shCon) were 




3.3.4. PRL-3 sensitizes cell growth to rapamycin treatment.  
Oncogenic activation of mTORC1 could enhance cell growth, survival, and proliferation 
by phosphorylating two main substrates, 4E-BP1and p70-S6K (Laplante and Sabatini, 
2012). Since cells overexpressing PRL-3 exhibited increased phosphorylation level of 
p70-S6K and 4E-BP1, it is necessary to determine the role of PRL-3 on mTOR in 
mediating cell growth. For this, the MTS assay was utilized to compare the effects of 
rapamycin treatment on HCT116-Vec or HCT116-PRL-3 cells. In untreated controls, 
there was an insignificant difference (10%) in cell growth between HCT116-Vec and 
HCT116-PRL-3 cells. In contrast, in the presence of 100 nM rapamycin, compared to 
untreated cells, HCT116-PRL-3 cell growth decreased by ~28% while HCT116-Vec cells 
decreased by ~7%. (Figure 3.6A, left panel). Similar results were observed with cells 
cultured under hypoxia conditions. Upon oxygen deprivation, compared to HCT116-Vec 
cells, HCT116-PRL-3 cells displayed 7% higher cell growth rate and showed heightened 
sensitivity to rapamycin treatment; at the present of 100 nM rapamycin, the 
HCT116-PRL-3 cell growth decreased by ~20% while HCT116-Vec cells decreased by 5% 
(Figure 3.6A, right panel). In addition, analysis of two parental colon cancer cell lines, 
DLD-1 (PRL-3 negative) and HCT116 (PRL-3 positive) (Figure 3.6B) showed that 
HCT116 cells were more sensitive to rapamycin treatment compared to DLD-1 cells. 
Compared to matched untreated controls, a significant reduction (~22%) in cell growth 
was observed in HCT116 cells after 48 hours incubation with 100 nM rapamycin 
compared with only 8% for DLD-1 cells. Similar results were also observed for cells 
under hypoxia (Figure 3.6C). Collectively, these data revealed that cells with higher 
PRL-3 expression are more sensitive to rapamycin treatment, implying that PRL-3 may 
sensitize cell growth to rapamycin treatment and mTOR signalling pathway might be 




Figure 3. 6 PRL-3 sensitizes cell growth to rapamycin treatment. (A) HCT116-Vec, 
HCT116-PRL-3 and HCT116-C104S cells were cultured in full media in the presence of 
DMSO (Ctrl) or 100 nM rapamycin (rapamycin) for 48 hours under normoxia (left panel) 
or hypoxia (right panel) condition. Relative proliferation rates were assessed by MTS assay. 
(B) DLD-1 cells and HCT116 cells lysed and western blot analysis was performed with 
antibodies against PRL-3 and GAPDH. (C) DLD-1 cells (PRL-3 negative) and HCT116 
cells (PRL-3 positive) were cultured in full media in the presence of DMSO (Ctrl) or 100 
nM rapamycin (rapamycin) for 48 hours under normoxia (left panel) or hypoxia (right 
panel) condition. Relative proliferation rates were measured using the MTS assay method. 
Three independent experiments were repeated and all data were shown as mean ± SE. 
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3.3.5. PRL-3 promotes cancer cell motility and invasiveness in a 
rapamycin-sensitive manner 
PRL-3 has been described to promote  cancer metastasis by increasing both motility and 
invasiveness of cancer cells (Al-Aidaroos and Zeng, 2010). To understand the 
mechanistic basis of this phenomenon, a wound healing assay on HCT116-Vec and 
HCT116-PRL-3 cells was conducted in the presence of DMSO or rapamycin. Supporting 
a pro-motile role for PRL-3, HCT116-PRL-3 cells displayed complete wound closure 
within 48 hours compared to HCT116-Vec cells which still had a large gap (Fig. 3.7A, 
panels i-ii). Remarkably, the motility of both cell lines were completely suppressed by 
rapamycin treatment (Fig. 3.7A, panels iii-iv). , suggesting a role for mTOR signalling in 
PRL-3-driven motility. 
Besides increased motility, the ability of tumour cells to degrade the ECM is an essential 
property for tumour invasion into surrounding tissues. Previously, overexpression of 
PRL-3 was reported to promote invasiveness of colon cancer cells (Peng et al., 2009) and 
correlate significantly with clinical hepatocellular carcinoma invasiveness (Zhao et al., 
2008). In agreement with these previous findings, overexpression of PRL-3 significantly 
increased the invasiveness of HCT116 cells through a basement matrix relative to control 
cells (Figure. 3.7B; p = 5.988E-05). Notably, rapamycin treatment suppressed 
invasiveness of PRL-3-overexpressing cells to similar levels as the control cells (Figure. 
3.7B). Collectively, these results suggest that mTOR is an important mediator of both 




Figure 3. 7 PRL-3 promotes cancer cell motility and invasiveness in a 
rapamycin-sensitive manner. (A) Monolayers of HCT116 cells stably overexpressing 
EGFP vector only (Vec) or EGFP-tagged wild-type PRL-3 (PRL-3) were ‘wounded’ and 
monitored over 48 h in the presence or absence of 100 nM rapamycin (Rapa). 
Phase-contrast images were captured at the indicated intervals. Dashed lines, boundary of 
cell monolayers on either side of the wound. Scale bar, 200 μm. (B) A transwell assay was 
used to determine the invasion potentials of HCT116-EGFP (Vec) or 
HCT116-EGFP-PRL-3 (PRL-3) cells. The images of invaded HCT116 cells stably 
overexpressing EGFP vector only (Vec) or EGFP-tagged wild-type PRL-3 (PRL-3) 
through a basement matrix were captured by microscopy after culturing in the presence or 
absence of 100 nM rapamycin. Cell numbers from three randomly-selected fields were 
counted and graphed. Results are depicted as mean ± S.D; ***p = 5.988E-05. Experiments 
were repeated twice with similar results. Scale bar, 100 μm.  
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3.3.6. PRL-3 upregulates production of MMP-2 and MMP-9  
MMP-2 and MMP-9 are enzymes that can degrade ECM and activate a number of growth 
factors, thus playing important roles in tumour invasion and metastasis (Gialeli et al., 
2011; Pratheeshkumar et al., 2012). Production of MMP-2 and MMP-9 has been reported 
to be up-regulated by increased mTOR activity and suppressed on rapamycin treatment 
(Pratheeshkumar et al., 2012; Zhang et al., 2004). Since PRL-3 activated mTOR 
signalling and enhanced cell invasiveness, the effect of PRL-3 on MMPs production was 
examined. Interestingly, overexpression of PRL-3 increased the production of MMP-2 
and MMP-9 at both mRNA and protein levels (Figure 3.8A). Subsequently, the relation 
between PRL-3-mediated mTORC1 activation and MMPs secretion was investigated. 
Compared to HCT116-Vec cells, HCT116-PRL-3 cells had higher levels of secreted 
MMP-2 and MMP-9 protein in conditioned media (Figure 3.8B). Notably, rapamycin 
treatment abolished PRL-3-induced secretion of MMP-2 and MMP-9, concomitant with 
suppression of phosphorylation of 4E-BP1 and p70-S6K (Figure 3.8B), suggesting that 
PRL-3 might upregulate MMP-2 production via increased mTORC1 activity. 
To further study the relationship of PRL-3 and mTORC1 activation, a publically 
available clinical dataset from colon cancer patients (GSE40967, n = 566) was analysed. 
PRL-3 expression was found to positively correlate with the mRNA expression of several 
matrix metalloproteinase proteins, including MMP-2 and MMP-9, in addition to mTOR 
regulators, LAMTOR 1 and 2 (lysosomal adaptor and mitogen-activated protein kinase 
(MAPK) and mTOR activator/regulator 1 and 2) (Table 3.1). Indeed, in HCT116 cells, 
overexpression of PRL-3 induced MMP-2 and MMP-9 expression at transcriptional level 
(Figure 3.8A), corroborating these clinical observations. 
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Interestingly, the cohort analysis of colon cancer patients revealed that MMP-2 
expression had a high prognostic value for patient survival when PRL-3 was highly 
expressed (p < 0.05; Figure 3.8C, right panel), but not when PRL-3 was expressed at 
lower levels (p = 0.851; Figure 3.8C, left panel). This suggested that MMP-2 may be 





Figure 3. 8 PRL-3 upregulates MMP2/9 production. (A) mRNA and protein levels 
of MMP-2 and MMP-9 in HCT116-Vec and HCT116-PRL-3 cells. (B) The 
conditioned media (CM) from HCT116-Vec or HCT116-PRL-3 cells after 
culturing in the presence or absence of 100 nM rapamycin for 24 h was harvested, 
concentrated, and analysed by immunoblotting with indicated antibodies. CM, 
conditioned media. TCL, total cell lysates from matched cell cultures. (C) 
Kaplan-Meier analysis of colorectal cancer patient cohort GSE40967 (n = 557) 
stratified by low or high PRL-3 expression. 
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TABLE 3. 1 Spearman’s correlation between PRL-3 gene expression and mTORC1 
related genes in colon cancer patient dataset (GSE 40967, n = 566) 
   Statistical significance, **p < 0.01, *p < 0.05 
 
3.4. Discussion 
In this study, a positive correlation between PRL-3 expression and mTOR activity was 
characterized in human cancer samples and the spontaneous breast tumor MMTV-PyMT 
mouse model. This result is consistent with previous reports that PRL-3 expression was 
highly upregulated (Wang et al., 2010) and mTOR activity was abnormally activated in 
many types of human cancers (Advani, 2010). In the MMTV-PyMT system, increasing 
expression of PRL-3 correlated with increased mTOR activity during tumour 
development, indicating a potential regulatory relationship. 
In addition, PRL-3 overexpression induced an aberrant activation of mTOR in cancer 
cells, as reflected by the hyperphosphorylation of the direct substrates of mTORC1, 
4E-BP1 and p70S6K. Interestingly, this phenomenon was still observed under conditions 
of oxygen, serum, or amino acid deprivation, wherein PRL-3 sustained mTORC1 
activation despite these growth-suppressing limitations. Furthermore, PRL-3 
overexpression enhanced cell motility and invasiveness, and promoted the expression and 
secretion of oncogenic collagenases MMP-2 and MMP-9. Importantly, these 
PRL-3-driven effects could be effectively suppressed by rapamycin treatment. These 
results collectively suggest that mTOR is an important effector of PRL-3-mediated 
tumour progression. 
 PRL-3 MMP-2 MMP-9 LAMTOR1 LAMTOR2 
PRL-3 Correlation Coefficient 













It has been previously reported that PRL-3 could promote proliferation of 
cytokine-dependent cells under limited cellular resources (Park et al., 2013b). In 
agreement with this result, PRL-3 overexpressing cells displayed a higher proliferative 
ability relative to their corresponding control cells under both normal and hypoxia 
conditions. Intriguingly, compared to control cells, cells with higher PRL-3 expression 
(either endogenous or exogenous) showed heightened sensitivity to rapamycin treatment. 
A possible explanation to this interesting observation is “oncogene addiction”, wherein 
inhibition of a dominant oncogene or hyperactive signalling pathway results in 
detrimental effects in tumor cells (Weinstein and Joe, 2008). Many oncogenes have been 
reported to confer addiction (Sharma and Settleman, 2007). For example, multiple 
myeloma cells and glioblastoma cell lines lacking PTEN (a suppressor of the mTOR 
signalling pathway) appear more sensitive to mTOR inhibitors, an effect thought to 
depend on the increased mTOR activity in PTEN-/- cells during tumour development 
(Neshat et al., 2001). Similarly, PRL-3 may induce hypersensitivity to mTOR inhibition 
due to hyperactive mTOR signalling addiction. Indeed, rapamycin treatment abolished 
the PRL-3-medicated cell proliferation, motility and invasion, suggesting a key role for 
mTOR as PRL-3’s oncogenic effector. 
Interestingly, MMP-2 expression correlated with shorter patient survival when PRL-3 
was highly expressed. Further analysis of a clinical dataset showed a positive correlation 
between PRL-3 expression levels and that of the downstream targets of mTORC1, 
MMP-2 and MMP-9. In cultured cells, PRL-3 overexpression resulted in an 
mTORC1-dependent increase in the production of oncogenic MMP-2 and MMP-9, two 
key collagenases involved in invasion and metastasis, and markers of poor prognosis in 
multiple cancers (Kurschat et al., 2002; van Kempen and Coussens, 2002). Although a 
previous report indicates the involvement of integrin beta-1-ERK signalling in 
PRL-3-mediated upregulation of MMP-2 (Peng et al., 2009), here we found that 
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PRL-3-induced MMP-2 and MMP-9 secretion was sensitive to rapamycin-mediated 
mTORC1 inhibition. It is possible that cross-activation between the Ras-MAPK and 
PI3K-mTORC1 pathways might account for the co-regulation of MMP-2 and MMP-2 
expression, leading to increased tumour invasiveness. Indeed, activation of the RAS-ERK 
pathway has been shown to increase mTORC1 activity through increased ERK and RSK 
signalling to the TSC complex (Mendoza et al., 2011).  
It was proposed that by endowing tumour cells with the ability to disseminate from 
unfavourable microenvironments (such as limited nutrient availability and/or limited 
oxygen) in search of more favourable conditions, PRL-3 may provide a strategic survival 
advantage to tumour cells via increased mTOR-dependent cell motility, invasiveness and 
production of MMP-2 and MMP-9. 
Collectively, these data reveal a novel pathway for PRL-3-mediated cancer progression 
via mTORC1 activation. 
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CHAPTER 4: PRL-3 REQUIRES AKT-TSC2-RHEB 






The activity of mTORC1 can be altered based on availability of growth factors, nutrients, 
energy and stress signals (Caron et al., 2010). By integrating signals from upstream 
signalling pathways, such as PI3K/Akt, Ras/Erk and LKB1/AMPK pathways, as well as 
Rag GTPases, mTOR thus functions as a master regulator of environmental cues within 
cells (Laplante and Sabatini, 2012) (Figure 4.1). 
PI3K/Akt and Ras/ERK are two mitogen-related signalling pathways, which are mediated 
by receptor tyrosine kinases (RTKs) and are important for cell growth and homeostasis 
(Hemmings and Restuccia, 2015; Sundaram, 2006). In the presence of growth factors, 
RTKs such as epidermal growth factor receptor, insulin receptor, and insulin-like growth 
factor receptor become activated. These RTKs then recruit the lipid kinase PI3K to the 
cellular membrane, resulting in the activation of PI3K and subsequent phosphorylation of 
its substrate phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P2) to 
phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) (Cantley, 2002). Accumulated 
PI(3,4,5)P3 attracts Akt to the cell membrane, where it is directly phosphorylated by 
phosphoinositide dependent protein kinase 1 (PDK1) and PDK2 (known as mTORC2), 
leading to its activation (Sarbassov et al., 2006; Vanhaesebroeck and Alessi, 2000). 
Alternatively, RTKs can also induce ERK activation through the Ras-Raf-MEK-ERK 
kinase cascade (Ma et al., 2005). These two effector kinases, Akt and ERK, finally 
induce mTORC1 activation via the TSC (tuberous sclerosis complex)-Rheb (Ras 




Figure 4. 1 Regulation of mTOR signalling pathway. 
In contrast, mTORC1 activity is suppressed by AMPK (Shaw, 2009). AMPK is a 
metabolism regulator that monitors cellular energy status, as reflected by the ratio of 
intracelluar AMP to ATP. In response to high AMP:ATP, such as during energy stresses 
such as glucose deprivation or ischemia, AMPK is activated by phosphorylation (Towler 
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and Hardie, 2007). Activated AMPK inhibits mTORC1 activity by directly 
phosphorylating two of its downstream targets, raptor and TSC (Gwinn et al., 2008; Inoki 
et al., 2003b). 
The activity of TSC, a heterotrimeric complex consisting of TSC1, TSC2 and TBC1D7, 
is regulated by many upstream signals through a series of phosphorylation events (Dibble 
et al., 2012). For example, AMPK activates TSC, while Akt and Erk inhibit its activity by 
phosphorylating the catalytic subunit TSC2 at distinct sites (Huang and Manning, 2008). 
TSC functions as a GTPase-activating protein (GAP) toward the small GTPase Rheb, 
negatively regulating mTORC1 activity by converting active GTP-bound Rheb into its 
inactive GDP-bound state at the lysosome (Menon et al., 2014; Tee et al., 2003). When 
Rheb is in its GTP-bound state, it directly interacts with mTORC1 and strongly 
stimulates its kinase activity. However, on activation, TSC will induce GDP-bound Rheb 
accumulation, leading to mTORC1 inhibition (Inoki et al., 2003a; Tee et al., 2003). 
Furthermore, to be physically activated by GTP-bound Rheb, mTORC1 must translocate 
to cellular endomembranes where Rheb is localized (Betz and Hall, 2013). This process 
requires participation of the Rag GTPases, which are a group of Ras-related small 
GTPases (Kim et al., 2008; Sancak et al., 2008). In mammals, Rag GTPases are 
comprised of four members: RagA, RagB, RagC, and RagD. They form obligate 
heterodimers composed of either RagA or RagB bound to RagC or RagD. The two 
members of the heterodimer have antithetical nucleotide loading states, wherefore when 





 are active forms, which are essential for the activation of mTORC1 (Sancak 
et al., 2008). Mechanistically, Ragulator, a Rag guanine nucleotide exchange factor, 
responds to the presence of amino acids by promoting the loading of RagA/B with GTP, 
thereby enabling Rag heterodimers to interact with mTOR and raptor and recruit 
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mTORC1 to lysosomes. This relocalization of mTORC1 leads to its encounter with 
GTP-bound Rheb, and activation (Bar-Peled et al., 2012; Sancak et al., 2010). 
Collectively, full mTORC1 activation is a two-pronged process, requiring upstream 
signals (such as PI3K/Akt, Ras/ERK or LKB1/AMPK) to activate the TSC-Rheb axis, 
and mTOR translocation to Rheb-resident endomembranes, particularly lysosomes (Betz 
and Hall, 2013). 
In chapter 3, PRL-3 was characterized to promote mTORC1 activation and consequent 
cell growth, motility and invasiveness under both normal and stressed conditions. 
However, the molecular mechanism underlying how PRL-3 activated mTORC1 was 
unknown. In this chapter, the mechanism of PRL-3-mediated activation of mTORC1 is 
explored. 
 
4.2. Experimental outline 
1. Investigate the effect of PRL-3 on TSC2-Rheb signalling. 
2. Define which upstream signalling pathway(s) activates PRL-3-driven 
TSC2-Rheb-mTORC1 activation. 
3. Study the effect of PRL-3 on mTOR translocation. 
4. Ascertain if Rag GTPase participates in PRL-3-mediated accumulation of 
lysosomal mTOR 





4.3.1 PRL-3 modulates TSC2-Rheb signalling  
One of the best-known upstream regulators of mTORC1 is the TSC-Rheb axis. TSC, a 
negative regulator of mTORC1, directly regulates GTPase activity of Rheb to modulate 
mTORC1 activity (Inoki et al., 2002). To understand how PRL-3 activates mTORC1, the 
effect of PRL-3 on TSC-Rheb axis was first assessed. In HCT116 cells, overexpression 
of EGFP-PRL-3 (PRL-3), but not the EGFP-PRL-3-C104S (catalytically-inactive mutant, 
C104S) or EGFP-vector control (Vec), induced phosphorylation of TSC2 on Ser939, a 
key functional site whose phosphorylation inhibits TSC2 activity (Aicher et al., 2001). 
This phenomenon was observed under normal, hypoxia, serum free and amino-acid 
starved conditions (Figure 4.2A). Consistent results were observed in HeLa cells 
overexpressing PRL-3 (Figure 4.2B). Conversely, depletion of endogenous PRL-3 with 
shRNA in HCT116 cells led to reduced TSC2 phosphorylation on Ser939 (Figure 4.2C). 
These results indicated that PRL-3 might suppress TSC2 activity.  
To validate whether inhibition of TSC2 by PRL-3 affected downstream Rheb activation, 
a Rheb activation assay was employed to study the levels of active GTP-bound Rheb 
(Rheb-GTP) in PRL-3-overexpressing cells. Relative to HCT116-Vec or HCT116-C104S 
cells, Rheb-GTP levels were higher in HCT116-PRL-3 cells under basal, hypoxic, 
serum-free and amino-acid starved conditions (Fig. 4.2D, lanes 2, 5, 8, 11, 14). Similar 
results were also found in HeLa cells (Figure 4.2E, lanes 2, 5, 8, 11, 14). These results 









Figure 4. 2 PRL-3 modulates TSC2-Rheb signalling. (A) HCT116-Vec, 
HCT116-PRL-3 and HCT116-C104S cells were cultured for 24 hours under normal (Ctrl), 
hypoxia (Hx), or serum free (SF) conditions, or cultured for 1 h under normal (Ctrl) or 
amino-acid starved (AA-) conditions, prior to lysis and western blot analysis with the 
antibodies against PRL-3, p-TSC2(S939), TSC2 and GAPDH. GAPDH used as a loading 
control. (B) Hela cells were transfected with empty EGFP vector (Vec), EGFP-PRL-3 
(PRL-3) or EGFP-C104S (C104S) plasmids, then cells were cultured and analyse as in (A). 
Western blot analysis was performed with indicated antibodies. (C) HCT116 cells 
expressing small hairpin RNA (shRNA) against PRL-3 (shPRL-3) or control shRNA 
(shCon) were cultured and analysed as in (A). (D) Cell lysates from (A) were 
immunoprecipitated with a configuration-specific anti-Rheb-GTP antibody and analysed 
by immunoblotting with the indicated antibodies. (E) Cell lysates from (B) were analysed 
as in (D). 
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4.3.2 PRL-3-mediated mTORC1 activation requires the activity of Akt but not 
Erk1/2 or AMPK 
The process of TSC-Rheb axis transmitting signals that converge on mTORC1 is 
controlled by many upstream signalling pathways, including the PI3K/Akt pathway, 
Ras/ERK pathway and LKB1/AMPK pathway (Huang and Manning, 2008). To elucidate 
which pathway(s) PRL-3 uses to activate the TSC2-Rheb-mTORC1 cascade, the 
activities of three pathways were examined by evaluating the activation-associated 
phosphorylation levels of their key kinases upon PRL-3 overexpression. Interestingly, 
compared with HCT116-Vec or HCT116-C104S cells, HCT116-PRL-3 cells displayed 
higher phosphorylation levels of Akt on Ser473, a critical activation site on this kinase 
(Bayascas and Alessi, 2005). This phenomenon was observed under normal, hypoxia, 
serum-free and amino-acid starved conditions (Figure 4.3A). However, the 
phosphorylation levels of two other kinases, Erk1/2 and AMPKα, showed no response to 
PRL-3 overexpression, despite a decrease in Erk1/2 phosphorylation and a slight increase 
in AMPKα phosphorylation in cells grown under stressed conditions (Figure 4.3A). 
Similar results were also observed in HeLa cells (Figure 4.3B). Moreover, suppression of 
endogenous PRL-3 in HCT116 cells reduced Akt phosphorylation under both normal and 
stressed conditions (Figure 4.3C). Notably, this PRL-3-mediated phosphorylation of Akt 
correlated well with a corresponding increase or decrease in phosphorylation of TSC2, 
mTOR and its downstream substrates, 4E-BP1 and p70S6K, suggesting that PRL-3 might 







Figure 4. 3 PRL-3 stimulates Akt activation. (A) HCT116-Vec, HCT116-PRL-3 or 
HCT116-C104S cells were cultured for 24 hours under normal (Ctrl), hypoxia (Hx), or 
serum free (SF) conditions, or cultured for 1 h under normoxia (Ctrl) or amino-acid starved 
(AA-) conditions. Cells were lysed and analysed by Western blotting with antibodies 
against the indicated proteins. GAPDH served as a loading control. (B) HeLa-Vec, 
HeLa-PRL-3 or HeLa-C104S cells were analyzed as in (A). (C) HCT116 cells expressing 
small hairpin RNA (shRNA) against PRL-3 (shPRL-3) or control shRNA (shCon) were 




Under all the conditions tested, the activity of AMPKα, unlike mTOR, was extremely 
low under normal and hypoxia conditions (Figure 4.3A-B). In contrast to this, high 
activities of Akt and Erk1/2 were detected under both normal and stressed conditions 
(Figure 4.3A-B). To confirm a role of Erk1/2 in PRL-3-mediated mTOR hyperactivation, 
U0126, a MEK specific inhibitor, was used to block Ras/ERK signalling. Inhibition of 
Erk1/2 activity did not dampen phosphorylation of TSC2, mTOR, 4E-BP1 and p70S6K, 
as well as Akt in both HCT116 and HeLa cells overexpressing PRL-3 (Figure 4.4AB). 
To validate the role of Akt in PRL-3-modulated TSC2-Rheb-mTORC1 activation, two 
approaches were employed to block Akt signalling: i) small interfering RNA 
(siRNA)-mediated depletion of AKT transcripts, and ii) small-molecule 
antagonist-mediated inhibition of Akt. siRNA-mediated AKT depletion reduced 
PRL-3-driven phosphorylation of TSC2, mTOR, and its downstream effectors, 4E-BP1 
and p70S6K (Figure 4.4C, panel 1). Likewise, treatment of cells with the Akt inhibitor 
VIII (AktiVIII), a highly selective and potent small-molecule inhibitor of Akt, also 
reduced PRL-3-induced hyperphosphorylation of TSC2, mTOR, 4E-BP1, and p70S6K 
(Figure 4.4C, panel 2). However, HCT116-PRL-3 cells still had higher 4E-BP1 and 
p70S6K phosphorylation relative to HCT116-Vec cells under these treatments, 
suggesting that Akt inhibition did not completely abolish the ability of PRL-3 to enhance 
p70S6K and 4E-BP1 phosphorylation. Similar results were also observed in HeLa cells 
(Figure 4.4C, panel 3-4).  
Collectively, while these results point to a role for Akt signalling in PRL-3-mediated 
mTORC1 hyperphosphorylation, the elevated activity of 4E-BP1 and p70S6K despite 
Akt inhibition hints at the existence of a secondary, Akt-independent PRL-3-driven 








Figure 4. 4 Akt activity is required for PRL-3-mediated hyperactivation of mTOR 
signalling. (A) Erk1/2 activity in HCT116-Vec or HCT116-PRL-3 cells was inhibited 
using U0126. Then the activity of TSC2-Rheb-mTOR pathway was analysed. (B) Erk1/2 
activity in Hela-Vec or Hela-PRL-3 cells was inhibited using U0126, then performed as 
in (A). (C) Panel 1. Akt in HCT116-Vec or HCT116-PRL-3 cells were transiently 
depleted using scrambled small interfering RNA (siCtrl) or AKT-targeting siRNA (siAKT) 
and cultured for 48 hours before analysis of Akt-TSC2-mTOR pathway activity. Panel 2. 
Akt in HCT116 Vec or PRL-3 cells was inhibited using Akt inhibitor VIII (AktiVIII) 
before analysis of Akt-TSC2-mTOR pathway activity. Panel 3. Akt in Hela-Vec or 
Hela-PRL-3 were transiently depleted using scrambled small interfering RNA (siRNA; 
siCon) or AKT-targeting siRNA (siAKT) and cultured for 48 hours before analysis of 
Akt-TSC2-mTOR pathway activity. Panel 4. Akt in Hela-Vec or Hela-PRL-3 was 
inhibited using Akt inhibitor VIII (AktiVIII) before analysis of Akt-TSC2-mTOR 
pathway activity. The ratio of phosphorylated/total band densities for Akt, 4E-BP1, and 
p70S6K were calculated and normalized to their cognate phosphorylated/total protein 
ratio in lane 3.  
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4.3.3 PRL-3 promotes the relocalization and accumulation of lysosomal mTOR 
Despite a reduction in overall mTOR phosphorylation levels in cells grown under 
hypoxia, serum deprivation, or amino acid starvation, the PRL-3-driven increase in 
phosphorylation of mTOR substrates 4E-BP1 and p70S6K under each of these stressors 
consistently appeared greater compared to the increase in mTOR S2448 phosphorylation 
itself. This suggests that the heightened resistance conferred by PRL-3 against mTOR 
inactivation under limited oxygen or nutrient supply might be due to some additional 
regulatory mechanism(s) on mTOR. In addition to canonical PI3K/Akt signalling, which 
regulates mTORC1 activity via TSC2-Rheb axis, mTORC1 is also tightly regulated by 
changes in its localization within the cell (Betz and Hall, 2013). To check the subcellular 
localization of mTOR, immunofluorescence analysis was conducted in HCT116-Vec and 
HCT116-PRL-3 cells. Unlike vector control cells, which had a somewhat more diffuse 
mTOR intracellular staining pattern (Figure 4.5, panels i-iii), PRL-3 overexpression in 
HCT116 cells promoted mTOR accumulation predominantly in perinuclear regions 
regardless of basal, hypoxic, or serum-fee conditions (Figure 4.5, panels iv-vi). 
Importantly, the perinuclear mTOR staining pattern was consistently well co-localized 
with the lysosomal membrane marker, LAMP2, under all conditions as well, indicating 
persistent lysosomal enrichment of mTOR in PRL-3-overexpressing cells despite oxygen 
or serum deprivation (Figure 4.5).  
Furthermore, the same experiment was repeated upon amino acid withdrawal, a stressor 
which typically results in rapid delocalization of mTORC1 away from lysosomes, 
effectively inactivating this kinase (Demetriades et al., 2014). In HCT116-Vec cells, 
amino acid starvation for 1 h resulted in a loss of mTOR/LAMP2 colocalization (Figure 
4.6A, panel ii). In contrast, mTOR/LAMP2 colocalization, albeit reduced, could still be 
observed in amino acid-starved HCT116-PRL-3 cells (Figure 4.6A, panel iv). The 
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ability of PRL-3 to maintain lysosomal mTOR accumulation suggested that PRL-3 
overexpression might ‘mimic’ amino acid stimulation, supporting our earlier observation 
of sustained mTOR activity induced by PRL-3 under basal and stressed conditions. To 
confirm these results, the mTOR/LAMP2 colocalization was analysed in HCT116 cells 
stably depleted of PRL-3. Depletion of endogenous PRL-3 resulted in a decrease in 
mTOR/LAMP2 colocalization not only under amino-acid starved conditions, but also 
under basal, amino-acid-replete conditions (Figure. 4.6B, panel iii, iv), suggesting an 
important role for endogenous PRL-3 in regulating the recruitment/retention of lysosomal 
mTOR. 
To further address if enhanced PI3K/Akt signalling might account for the increased 
lysosomal localisation of mTOR, we treated HCT116 cells with an Akt inhibitor and 
analysed mTOR/LAMP2 colocalization. No changes in mTOR/LAMP2 colocalization 
were observed under these conditions (Figure 4.7), suggesting that the increased 




Figure 4. 5 PRL-3 promotes the accumulation of lysosomal mTOR. (A) 
Immunofluorescence analysis of mTOR and LAMP2 in HCT116-Vec or HCT116-PRL-3 
cultured for 24 hours under normal (Ctrl), hypoxia (Hx) or serum Free (SF) conditions. 
Antibodies against human LAMP2 and mTOR were used. Red, mTOR signal; green, 
LAMP2 signal; merge, merged mTOR, LAMP2, and DNA (DAPI) signals. Scale bar, 10 
μm. A zoomed area within each merged panel enables better visualize mTOR/LAMP2 







Figure 4. 6 PRL-3 modulates the relocalization of lysosomal mTOR under 
amino-acid starved condition. (A) Immunofluorescence analysis of mTOR and LAMP2 
in HCT116-Vec and HCT116-PRL-3 cultured for 1 hours in full media (Ctrl) or 
amino-acid starvation media (AA-). Antibodies against human LAMP2 and mTOR were 
used. Red, mTOR signal; green, LAMP2 signal; merge, merged mTOR, LAMP2, and 
DNA (DAPI) signals. Scale bar, 10 μm. A zoomed area within each merged panel 
enables better visualize mTOR/LAMP2 colocalization. Scale bar, 10 μm. (B) HCT116 
cells stably expressing small hairpin RNA (shRNA) against PRL-3 (shPRL-3) or control 




Figure 4. 7 PRL-3-modulated relocalization of lysosomal mTOR is Akt-independent. 
HCT116-Vec and HCT116-PRL-3 cells were treated with DMSO or Akt Inhibitor VIII 
(AktiVIII) for 30 min and analyzed by dual dual immunfluoresence using antibodies 
against mTOR and LAMP2. Red, mTOR signal; green, LAMP2 Scale bar, 10 μm. 
89 
 
4.3.4 PRL-3 promotes mTOR hyperactivation through RagGTPase-mediated 
lysosomal relocalization 
The Rag small GTPases are critical regulators for mTOR lysosomal relocalization and 
activation. Upon amino acid stimulation, Rag GTPases associate with mTORC1 as 
heterodimers, recruiting it to late endosomal and lysosomal compartments for subsequent 
Rheb-mediated activation (Sancak et al., 2008).  
To explore the role of Rag GTPases in PRL-3-induced lysosomal accumulation of mTOR, 
Rag GTPase heterodimeric complexes (RagB-RagC) were co-expressed in either 
HCT116-Vec or HCT116-PRL-3 cells, and binding affinities of Rag GTPases to mTOR, 
raptor, and rictor were examined. Compared with control cells, PRL-3 overexpression 
increased the binding affinity of Rag GTPase heterodimers to both mTOR and raptor, a 
component of mTORC1, under basal conditions (Figure 4.8A, lane 2). Notably, no 
binding between Rag GTPases and rictor, a component of mTORC2, was observed in 
either cell line (Figure 4.8A). Importantly, PRL-3-overexpressing cells maintained strong 
binding of Rag GTPase heterodimers to mTORC1 (mTOR and raptor) persistently under 
hypoxic and serum-free conditions (Figure 4.8A, lanes 4, 6). Expectedly, the 
PRL-3-mediated Rag-mTORC1 interaction was slightly reduced under amino-acid 
starved condition. Consistently, HCT116 cells depleted of PRL-3 displayed reduced 
Rag-mTOR-Raptor interaction under all basal and stressed conditions (Figure 4.8B, 
lanes 2, 4, 6 and 8). These results are in agreement with our observations showing that 
persistent lysosomal accumulation and elevated mTOR signalling were induced by 
PRL-3 under both basal and stressed conditions. Therefore, a correlation seems to exist 




To test whether elevated Rag GTPase activity affected PRL-3-mediated mTORC1 
activation, dominant-negative GST-tagged RagBT54L-RagDQ121L heterodimers (Rag
DN
) 
or empty vector (Ctrl) were co-expressed in either HCT116-Vec or HCT116-PRL-3 cells 
and phosphorylation levels of various components of the Akt-mTOR signalling pathway 
were examined. Interestingly, overexpression of Rag
DN
 did not rescue mTOR 
phosphorylation levels (Figure 4.8C, lane 4), despite potently blocking PRL-3-mediated 
accumulation of mTOR at LAMP2-enriched puncta (Fig. 4.8D, panel vi). However, a 
reduction in phosphorylation levels of p70S6K and 4E-BP1 was observed, suggesting 
partial suppression of mTOR kinase activity and downstream signalling by Rag
DN
 
(Figure 4.8AC, lane 4). Notably, no changes in PRL-3-induced phosphorylation of Akt 
were observed upon Rag
DN
 expression (Figure 4.8C, lane 4), in agreement with the 
earlier data suggesting that Akt lay upstream of mTORC1. 
Taken together, these data show that independently of activation of mTOR via the 
PI3K-Akt-TSC2-Rheb pathway, PRL-3 also promotes mTORC1 lysosomal translocation 








Figure 4. 8 PRL-3 promotes the accumulation and activation of lysosomal mTOR via 
increased Rag GTPase binding. (A) HCT116-Vec or HCT116-PRL-3 cells were 
co-transfected with GST-RagB/C and cultured for 24 hours under normal (Ctrl), hypoxic 
(Hx), serum free (SF) or amino-acid starved conditions before GST pull-down and analysis 
by immunoblotting. Top panel, GST-enriched fraction; bottom panel, total protein input. 
(B) HCT116 cells stably expressing small hairpin RNA (shRNA) against PRL-3 (shPRL-3) 
or control shRNA (shCon) were performed and analysed as in (A). (C) HCT116-Vec or 







) for 24 hours, western blot was analyzed with the indicated 
antibodies. (D) HCT116-Vec or HCT116-PRL-3 cells were transfected with empty vector 






) for 24 h, or starved of amino acid 
for 1 h, before dual immunfluoresence analysis using antibodies against mTOR and 




In this chapter, PRL-3 was characterized to function as a unique mTOR regulator in that 
it both: 1) activates TSC2-Rheb via Akt signalling pathway; and, in parallel, 2) promotes 
recruitment of mTORC1 to Rheb-resident lysosomes via interaction with Rag GTPase 
proteins, leading to sustained, efficient mTORC1 activation under basal and stressed 
conditions. This novel mechanism might explain how PRL-3 promotes cancer 
progression through the mTOR signalling pathway. 
As a molecular switchboard regulating mTORC1 activation, the activity of TSC2 was 
previously reported to be controlled by many upstream regulators via direct 
phosphorylation at different residues (Huang and Manning, 2008), including 
Akt-mediated phosphorylation of Ser939 and Thr1462 (Roux et al., 2004), 
Erk1/2-mediated phosphorylation of Ser540 and Ser644 (Ma et al., 2005) and 
AMPK-mediated phosphorylation of Thr1227 and Ser1345(Corradetti et al., 2004). 
Overexpression of PRL-3 induced Rheb GTPase activity and TSC2 phosphorylation on 
Ser939 under both normal and stressed conditions, raising the possibility that Akt may be 
involved in this regulation. Indeed, activation-associated phosphorylation of Akt was 
found to increase upon PRL-3 overexpression, even under hypoxia, serum-free and 
amino-acid starved conditions. These results are supported by previous studies, showing 
that PRL-3 activates Akt signalling via various pathways, including downregulation of 
phosphatase and tensin homologue (PTEN) (Wang et al., 2007a) and hyperactivation of 
receptor tyrosine kinases (Al-Aidaroos et al., 2013). However, different from the earlier 
report that inhibition of PRL-3 reduces Erk1/2 phosphorylation in A549 cells (Ming et al., 
2009), PRL-3 overexpression showed no effect on Erk1/2 phosphorylation in both 
HCT116 and HeLa cells, which might be explained by cell-specific function of PRL-3. 
Moreover, inhibition of Akt, but not Erk1/2, suppressed PRL-3-mediated 
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TSC2-Rheb-mTORC1 activity. Surprisingly, this suppression is not complete. Minor 
increases in phosphorylation levels of 4E-BP1 and p70S6K, but not mTOR, still could be 
observed in PRL-3-overexpressed cells despite Akt inhibition, indicating that besides the 
enhancement of Akt-TSC2-Rheb cascade, another Akt-independent PRL-3-driven 
mTORC1 activation mechanism exists. 
Furthermore, PRL-3 was shown to induce mTOR accumulation at lysosomes where it can 
be fully activated, leading to mTORC1 activation. In agreement with previous reports 
that lysosomal positioning of mTOR is regulated by Rag GTPases in response to amino 
acids (Jewell et al., 2013), Rag GTPases are implicated in PRL-3-mediated lysosomal 
mTOR accumulation, as the mTOR/LAMP2 colocalization could be effectively abolished 
upon overexpression of dominant-negative Rag
DN
 GTPase in HCT116-PRL-3 cells. 
Interestingly, PRL-3 increased the binding affinity of Rag GTPase to its target proteins, 
mTOR and Raptor, under both basal and stressed conditions, suggesting an elevated 
GTPase activity. Such PRL-3-driven Rag-GTP accumulation, which was previously 
reported to enhance mTOR recruitment to lysosomes (Jewell et al., 2013), occurred in an 
Akt-independent manner, thereby constituting a novel mechanism of mTORC1 regulation 
distinct from PI3K/Akt activation by PRL-3. This yet-uncharacterized, Akt-independent 
pathway for PRL-3 to activate Rag GTPases might occur via the regulation of Rag 
activity via the Ragulator complex which, by promoting Rag-GTP formation, has been 
shown to be necessary for targeting mTORC1 to lysosomes (Bar-Peled et al., 2012; 
Sancak et al., 2010). 
Intriguingly, the Rag-mTOR binding is unlikely to solely account for the mTOR-LAMP2 
colocalization observed. Particularly, in amino acid-starved HCT116-PRL-3 cells, the 
slight reduction in the Rag-mTOR interaction (Figure 4.8A, lane 8) did not correlate 
exactly with the loss of colocalization between mTOR and LAMP2 (Figure 4.6A, panel 
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iv). Similarly, in amino acid-replete conditions, the difference in Rag-mTOR interaction 
between HCT116-Vec and HCT116-PRL-3 cells (Figure 4.8A, lanes 1-2) did not 
perfectly recapitulate the difference in mTOR/LAMP2 colocalization (Figure 4.6A, 
panels i and iii). A possible explanation is that the Rag GTPase-mTOR interaction seen 
in pull-down experiments might also persist on non-LAMP2 positive endomembranes, 




CHAPTER 5: PRL-3 PROTECTS AGAINST 






In response to environmental stress, cells integrate external stress signals to determine 
death or survival. Among the various stress-responsive signalling pathways, the 
mitogen-activated protein kinase (MAPK) family proteins are widely used by eukaryotic 
cells to transduce extracellular signals into intracellular responses, and are extremely 
crucial for the maintenance of cellular homeostasis  (Cowan and Storey, 2003). 
MAPKs are a group of serine/threonine protein kinases involved in many fundamental 
cellular processes, including cell growth, differentiation, inflammation, and apoptosis 
(Cargnello and Roux, 2011) (Figure 5.1). Conventional MAPKs consist of four major 
subfamily members: ERKs, JNKs, ERK5 and p38 MAPKs (Zarubin and Han, 2005). 
They are highly conserved and share an activation loop designated as “Thr-X-Tyr”. Dual 
Thr and Tyr phosphorylation in this activation loop fully activates MAPKs activity 
(Cargnello and Roux, 2011). Activation of MAPKs is achieved by a three-tier protein 
kinase cascade, where MAPKs are phosphorylated by dual specificity serine-threonine 
MAPK kinases (MAPKKs), while these MAPKKs are phosphorylated and activated by 
upstream MAPKK kinases (MAPKKKs) (Roux and Blenis, 2004). Notably, among these 
conventional MAPKs, the ERKs are preferentially activated by mitogens, while JNKs 
and p38 MAPKs are mainly activated by environmental stresses such as inflammatory 
stimulation, heat shock, UV irradiation, and oxidative stress (Cobb et al., 1994; Johnson 
and Lapadat, 2002). 
In mammals, the p38 MAPKs are represented by four isoforms: p38, p38β, p38δ, and 
p38γ, which share approximately 60% homology in their amino acid sequences (Zarubin 
and Han, 2005). These four isoforms are encoded by different genes, exhibiting distinct 
expression patterns and affinities for upstream activators and downstream effectors (Ono 
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and Han, 2000). Unlike the ubiquitous p38, the other three isoforms are expressed in a 
tissue‐specific manner (Cuadrado and Nebreda, 2010). Notably, p38 knock‐out mice are 
embryonically lethal, while deficiency of other p38 isoforms does not affect normal 
development in mice (Beardmore et al., 2005; Sabio et al., 2005; Tamura et al., 2000). 
p38 MAPKs are known to be activated by two major MAPKKs, MKK3 and MKK6. 
MKK6 is a common activator of all four p38 isoforms, whereas MKK3 is unable to 
activate p38 (Enslen et al., 2000). Besides MKK3 and MKK6, MKK4, an upstream 
kinase of JNKs, can also activate p38 and p38 in specific cell types (Brancho et al., 
2003). Once activated, p38 MAPKs can orchestrate cellular responses by directly 
phosphorylating and regulating various substrates, which range from protein kinases to 
transcription factors (Sui et al., 2014).  
The function of p38 MAPK (hereafter referred to as p38 MAPK) in cancer is 
controversial. Although some reports have described a potential oncogenic function for 
p38 MAPK, the majority of studies suggest p38 MAPK serves as a tumour suppressor by 
playing a critical role in the regulation of apoptosis (Peter and Dhanasekaran, 2003; Sui 
et al., 2014). Apoptosis is a form of programmed cell death that can maintain body health 
by eliminating damaged or defective cells. Defective or inefficient apoptosis is one of the 
major reasons leading to cancer development. When too little apoptosis occurs, malignant 
cells will survive and expand, leading to tumour progression and metastasis (Lowe and 
Lin, 2000). Although a few studies have reported that p38 MAPK suppressed apoptosis 
in some cell lines, a growing body of evidence showed that activation of p38 MAPK 
induces apoptosis in various types of cells, supporting a pro-apoptotic role of p38 MAPK 




Figure 5. 1 Regulation of MAPKs signalling. 
PRL-3 plays an important role in the regulation of cancer cell survival. Several reports 
have shown that PRL-3 causes drug resistance in cancer cells by suppressing apoptotic 
cell death (Min et al., 2010; Qu et al., 2014). However, the underlying mechanism(s) of 
PRL-3-mediated suppression of apoptosis remains largely unknown. Therefore, an 
understanding of the mechanism(s) involved would be a pivotal step to overcome 
PRL-3-induced drug resistance and improve cancer therapeutic efficacy. Despite the 
importance and involvement of p38 MAPK and PRL-3 in apoptosis regulation and cancer 
development, only two published papers have mentioned this interaction, and they 
described contradicting observations. One paper found that PRL-3 depletion led to p38 
MAPK activation in MEFs (Basak et al., 2008), while another paper reported that PRL-3 
overexpression induced p38 MAPK activation in A431 cancer cells (Al-Aidaroos et al., 
2013). Hence, the interaction between p38 MAPK and PRL-3 requires further 
investigation. In this study, the anti-apoptotic role of PRL-3 is validated, accompanied by 
the molecular investigation for this phenomenon.  
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5.2. Experimental outline 
1. Investigate the protective effect of PRL-3 in CoCl2-induced apoptosis. 
2. Define which signalling pathway(s) are involved in PRL-3-mediated anti-apoptosis. 
3. Determine whether PRL-3-mediated inhibition of p38 MAPK phospho-activation is 
ROS-independent. 




5.3.1. PRL-3 suppresses CoCl2-induced apoptosis 
To investigate the role of PRL-3 in cell death, DLD-1 cells stably expressing 
EGFP-PRL-3 (PRL-3), EGFP-PRL-3-C104S (C104S; catalytically-inactive mutant), or 
empty EGFP vector (Vec), were generated and then treated with cobalt chloride (CoCl2), 
a hypoxia-mimetic agent which has been previously reported to induce reactive oxygen 
species (ROS) generation and cell death (Kotake-Nara and Saida, 2007; Liu et al., 2008a). 
Dose response and time course analysis revealed higher sensitivity of DLD-1-Vec and 
DLD-1-C104S cells to CoCl2 toxicity, with cells appearing smaller and rounded up. In 
contrast, DLD-1-PRL-3 cells maintained similar morphology despite similar CoCl2 
treatment dose or duration (Figure 5.2A-B).  
As cell shrinkage is a typical morphological feature of cell apoptosis (Saraste and Pulkki, 
2000), these data implied that PRL-3 may block CoCl2-induced apoptosis in a 
phosphatase activity-dependent manner. However, CoCl2 has been shown to induce both 
apoptotic and necrotic cell death (Jung et al., 2008; Rovetta et al., 2013). To confirm the 
pathway involved, cells were treated with CoCl2 in the presence or absence of an 
apoptosis inhibitor, z-VAD-fmk, or a necrosis inhibitor, necrosulfonamide (NSA) 
(Nicholson et al., 1995; Zhou et al., 2012b). Interestingly, compared with control and 
CoCl2 treatment groups, z-VAD-fmk, but not NSA, effectively abolished CoCl2-induced 
cell shrinkage of DLD-1-Vec and DLD-1-C104S cells (Figure 5.3A). Notably, these 
treatments did not alter the cell morphology of DLD-1-PRL-3 cells (Figure 5.3A). Cell 
viability measurements revealed that the viability of DLD-1-Vec and DLD-1-C104S cells 
decreased to ~38% and ~34% respectively, while the viability of DLD-1-PRL-3 cells 
only decreased to ~70% (Figure 5.3B). Intriguingly, z-VAD-fmk treatment significantly 
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rescued CoCl2-induced loss of cell viability for DLD-1-Vec and DLD-1-C104S cells to 
~59% and ~61% respectively (p < 0.01; Figure 5.3B). Similar results were observed in 
MCF-7 cells (Figure 5.3C-D). 
Poly(ADP-ribose) polymerase (PARP) cleavage, a hallmark of caspase activation and 
apoptosis (Saraste and Pulkki, 2000), was next assessed to determine the involvement of 
caspase activation in CoCl2-induced cell death. Western blot analysis by using a 
cleaved-PARP-specific antibody revealed that CoCl2 induced the PARP cleavage in 
DLD-1-Vec and DLD-1-C104S cells (Figure 5.4A). This CoCl2-induced PARP cleavage 
was dose- and time-dependent, which became significant after 5 μM CoCl2 treatment for 
24 hours. Interestingly, compared to DLD-1-Vec or DLD-1-C104S cells, PARP cleavage 
was dramatically reduced in DLD-1-PRL-3 cells upon CoCl2 treatment (Figure 5.4A). 
Similar results were obtained in MCF-7 cells (Figure 5.4B). Collectively, these data 









Figure 5. 2 PRL-3 suppresses CoCl2-induced cell death. (A) DLD-1-Vec, 
DLD-1-PRL-3 and DLD-1-C104S cells were treated with CoCl2 at the concentrations of 0, 
2, 5 or 10 μM for 24 h. Cell morphology was captured using microscopy. (B) DLD-1-Vec, 
DLD-1-PRL-3 and DLD-1-C104S cells were incubated with 5 μM CoCl2 for 0, 12, 24 or 










Figure 5. 3 z-VAD suppresses CoCl2-induced cell death. (A) DLD-1-Vec, 
DLD-1-PRL-3 and DLD-1-C104S cells were treated with 5 μM CoCl2 in the presence or 
absence of z-VAD-fmk (50 μM), or Necrosulfonamide (NSA) (10 μM) for 24 h. (B) 
DLD-1-Vec, DLD-1-PRL-3 and DLD-1-C104S cells were treated as in (A). Cell viability 
was then assayed using the MTS assay. Data are from three replicate experiments (mean ± 
SEM). (E) MCF-7 cells stably overexpressing EGFP vector only (Vec), EGFP-tagged 
wild-type PRL-3 (PRL-3) or EGFP-tagged catalytic-inactive PRL-3 C104S (C104S) were 
treated as in (A). (F) MCF-7-Vec, MCF-7-PRL-3 and MCF-7-C104S cells were treated as 
in (A). Then cell viability was assayed using MTS assay. Data are from three replicate 




Figure 5. 4 PRL-3 reduces PARP cleavage. (A) DLD-1-Vec, DLD-1-PRL-3 and 
DLD-1-C104S cells were treated with CoCl2 at the concentrations of 0, 2, 5 or 10 μM for 
24 h. Cells were lysed and western blot analysis was performed with antibodies against 
PRL-3, cleaved-PARP (Asp214) and GAPDH. GAPDH used as a loading control. (B) 
MCF-7-Vec, MCF-7-PRL-3 and MCF-7-C104S cells were treated with 5 μM CoCl2 for 24 
h. Cells were subsequently lysed and analysed as in (A).  
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5.3.2. p38 MAPK participates in PRL-3-mediated cell survival 
Determination of cell fate is coordinated by pro-survival and pro-apoptotic signals (Fulda 
et al., 2010). It is known that cancer cells can sustain survival and inhibit apoptosis via 
activation of diverse pro-survival signalling pathways (Brumatti et al., 2010; Buchheit et 
al., 2014). Some pro-survival pathways, such as Ras/Erk, PI3K/Akt, Src/STAT and 
JAK/STAT pathways, were previously reported to be activated in PRL-3-overexpressed 
cancer cells (Liang et al., 2007; Ming et al., 2009; Walls et al., 2013; Wang et al., 2007a). 
To examine whether these oncogenic pathways are involved in PRL-3-mediated cell 
survival, specific inhibitors were utilized to block them. Interestingly, upon inhibition of 
Ras/Erk (with U0126), PI3K/Akt (with LY294002), Src/STAT(with PP2), or  Jak/STAT 
(with AG490), DLD-1-PRL-3 cells still displayed high resistance to CoCl2-mediated cell 
death, suggesting that these signalling pathways might be not implicated in 
PRL-3-mediated cell survival (Figure 5.5A). PRL-3 was previously shown to promote 
autophagy under starvation in A2780 cells (Huang et al., 2014), which might increase 
stress tolerance and protect the cell from apoptosis (He and Levine, 2010). To determine 
if autophagy participates in PRL-3-mediated anti-apoptosis, Bafilomycin A1 (BafA1) 
was employed to inhibit autophagy. However, upon BafA1 treatment, PRL-3 still 
displayed an anti-apoptotic behavior in response to CoCl2-induced cell death (Figure 
5.5A). 
JNK and p38 MAPK signalling pathways are two well-known pro-apoptosis pathways 
which are activated in response to chemotherapeutic agents, resulting in cell death (Sui et 
al., 2014). To determine the mechanism by which PRL-3 inhibits CoCl2-induced 
apoptosis, cells were pretreated with the p38 MAPK inhibitor SB30580 or JNK inhibitor 
SP60125, prior to CoCl2 exposure. Surprisingly, blockade of p38 MAPK, but not JNK, 
conferred apoptosis-resistance in both DLD-1-Vec and DLD-1-C104S cells upon CoCl2 
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exposure (Figure 5.5B). This observation was further supported by cell viability assays. 
As shown in Figure 5.5C, SB30580 treatment significantly rescued the CoCl2-induced 
loss of cell viability from 34% to 62% in DLD-1-Vec cells, and from 35% to 56% in 
DLD-1-C104S cells. 
Furthermore, the activities of MAPK signalling pathways were evaluated upon CoCl2 
treatment by western blotting analysis. Dose response analysis showed that CoCl2 
induced phospho-activation of Erk1/2, JNK and p38 MAPKs (Figure 5.6A). However, 
compared with DLD-1-Vec and DLD-1-C104S cells, DLD-1-PRL-3 cells showed 
significantly less phosphorylation of p38 MAPK, suggesting PRL-3 may block the 
activation of p38 MAPK signalling pathway. Likewise, time course analysis revealed that 
phosphorylated p38 MAPK was highly expressed in CoCl2-treated DLD-1-Vec and 
DLD-1-C104S cells, yet completely suppressed in DLD-1-PRL-3 cells (Figure 5.6B). 
Notably, this PRL-3-mediated inhibition of p38 MAPK phosphorylation was well 
correlated with a decrease in PARP cleavage. Thus, these data suggest PRL-3 may 








Figure 5. 5 p38 MAPK inhibitor protects against CoCl2-induced apoptosis. (A) 
DLD-1-Vec, DLD-1-PRL-3 and DLD-1-C104S cells were pretreated with U0126 (10 μM), 
LY294002 (10 μM), PP2 (10 μM), AG490 (10 μM) or BafA1 (10 μM) for 1 h, and then 5 
μM CoCl2 was added for 24 h incubation. Cell morphology was captured using microscopy. 
(B) DLD-1-Vec, DLD-1-PRL-3 and DLD-1-C104S cells were pretreated with SP60125 
(10 μM) or SB30580 (10 μM) for 1 h, and then 5 μM CoCl2 was added for 24 h 
incubation, and then cell morphology was captured using microscopy. (C) After treatment 
as described in panel B, cell viability was assayed using MTS assay. Data were from three 




Figure 5. 6 p38 MAPK participates in PRL-3-mediated cell survival. (A) DLD-1-Vec, 
DLD-1-PRL-3 and DLD-1-C104S cells were treated with CoCl2 at the concentrations of 0, 
2, 5 or 10 μM for 24 h. Then cells were lysed and western blot analysis was performed with 
the indicated antibodies. GAPDH used as a loading control. (B) DLD-1-Vec, 
DLD-1-PRL-3 and DLD-1-C104S cells were incubated with 5 μM CoCl2 for 0, 12, 24 or 
36 h time intervals. Then cells were lysed and analysed as in (A).  
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5.3.3. PRL-3-mediated inhibition of p38 MAPK activation is ROS-independent 
CoCl2 is a ROS inducer (Kotake-Nara and Saida, 2007). Excess ROS could promote 
oxidation of cellular macromolecules and impair protein function, leading to apoptosis 
(Simon et al., 2000). Many reports have demonstrated that ROS induces cell death in 
response to drug treatment via the activation of p38 MAPK (Choi et al., 2015; Dong et al., 
2015; Lin et al., 2014). 
To evaluate the effect of PRL-3 on ROS generation, the level of ROS in cells was 
measured by the CM-H2DCFDA (5-(and-6)-chloromethyl-2’,7’ 
-dichlorodihydrofluorescein diacetate) fluorescence assay. As shown in Figure 5.7A, 
compared with untreated cells, CoCl2-treated cells showed higher levels of 
CM-H2DCFDA fluorescence, indicating increased ROS generation. However, no 
significant difference in CM-H2DCFDA fluorescence intensity was observed between 
DLD-1-Vec, DLD-1-PRL-3, and DLD-1-C104S cells (Figure 5.7B). More precisely, 
upon CoCl2 treatment, the intracellular level of ROS increased by 1.66 fold in 
DLD-1-Vec cells, 1.63 fold in DLD-1-PRL-3 cells, and 1.71 fold in DLD-1-C104S cells 
(Figure 5.7C). These data suggest PRL-3 does not affect ROS generation in DLD-1 cells. 
Next, the activities of ROS-sensitive ASK1, and its downstream effectors MKK4 and 
MKK3/6, which in turn regulate p38 MAPK (Han et al., 2010), were quantified by 
western blotting analysis. Dose response analysis demonstrated that CoCl2 induced the 
phosphorylation of ASK1 and MKK4, but not MKK3/6. However, PRL-3 overexpression 
did not alter their phosphorylation levels (Figure 5.7D). Similar results were observed 
over a time course analysis (Figure 5.7E). These data suggest that while CoCl2 can 
induce apoptosis through the activation of the ROS via the ASK1-MKK4-p38 MAPK 








Figure 5. 7 PRL-3-mediated inhibition of p38 MAPK activation is ROS-independent. 
(A) DLD-1 cells overexpressing pCMV-vector (Vec), pCMV-PRL-3 (Vec) (PRL-3) or 
pCMV-PRL-3-C104S (C104S) were treated with 5 μM CoCl2 for 24 h. Intracellular ROS 
were detected by staining with CM-H2DCFDA that turns into a fluorescent compound 
upon oxidation. Fluorescence images were captured using confocal microscope. (B) Cells 
were treated as in (A), CM-H2DCFDA fluorescence intensity was analysed by FACS. (C) 
Cells were analysed as in (B), data were from three replicate experiments (mean ± SEM). 
(D) DLD-1-Vec, DLD-1-PRL-3 and DLD-1-C104S cells were treated with CoCl2 at the 
concentrations of 0, 2, 5 or 10 μM for 24 h. Then cells were lysed and western blot analysis 
was performed with the indicated antibodies. GAPDH served as a loading control. (E) 
DLD-1-Vec, DLD-1-PRL-3 and DLD-1-C104S cells were incubated with 5 μM CoCl2 for 
0, 12, 24 or 36 h. Cells were subsequently lysed and analysed as in (E). Scale bar, 200 μm. 
116 
 
5.3.4 PRL-3 binds p38 MAPK and promotes its dephosphorylation in vitro 
To further explore how PRL-3 might downregulate the phosphorylation of p38 MAPK, 
the interaction of PRL-3 with p38 MAPK was analysed using co-immunoprecipitation. 
Notably, in DLD-1 cells, PRL-3 could directly bind to p38 MAPK, but not its upstream 
regulators ASK1 (Figure 5.8A). Moreover, reverse co-immunoprecipitation validated the 
interaction between PRL-3 and p38 MAPK in DLD-1 cells (Figure 5.8B). 
Since PRL-3 is a phosphatase, the interaction between PRL-3 and p38 MAPK suggested 
that PRL-3 might dephosphorylate p38 MAPK directly. To test this idea, recombinant 
PRL-3 was incubated with p38 MAPK immunopurified from DLD-1 cells and assayed 
in-vitro using a malachite green phosphate-release assay. In this assay, an increase in 
malachite green corresponds to an increase in released phosphate, such as upon protein 
dephosphorylation. Interestingly, GST-PRL-3, but not GST, resulted in p38 MAPK 
dephosphorylation (Figure 5.8C). Collectively, these data suggest PRL-3 may protect 





Figure 5. 8 PRL-3 binds p38 MAPK and promotes its dephosphorylation in vitro. (A) 
DLD-1 cells transfected with pEGFP-C1 vector alone (GFP-Ctrl) or pEGFP-PRL-3 
(GFP-PRL-3) were incubated with or without 5 μM CoCl2 for 24 h. Anti-EGFP 
immunoprecipitates from DLD-1-EGFP-Ctrl or DLD-1-EGFP-PRL-3 were probed 
with antibodies against PRL-3, p38, ASK1 and GAPDH. (B) DLD-1 cells were 
co-transfected with pEGFP-PRL-3 and pCDNA3-Flag-p38 or pCDNA3 vector only. 
Cells were then incubated with or without 5 μM CoCl2 for 24 h. Anti-Flag 
immunoprecipitates from cells were analyzed by western blotting, and probed with 
antibodies against p38, PRL-3, ASK1 and GAPDH as indicated. (C) Recombinant 
GST or GST-PRL-3 was incubated with Flag-tagged immunoprecipitates purified 
from DLD-1 cells expressing Flag vector alone (Flag-ctrl) or Flag-tagged p38 
(Flag-p38). Malachite green phosphatase assay was conducted as described in the 





In this chapter, PRL-3 was shown to suppress CoCl2-induced apoptosis by preventing 
cellular shrinkage, promoting cell viability, and reducing PARP cleavage. These results 
are consistent with previous reports that PRL-3 could prevent cell death and sustain cell 
survival under stress conditions (Huang et al., 2014; Lian et al., 2012; Park et al., 2013a; 
Qu et al., 2014).  
To define how PRL-3 protected against CoCl2-induced apoptosis, multiple pro-survival 
signalling pathways, including Ras/Erk, PI3K/Akt, Src/STAT, JAK/STAT and autophagy, 
which were previously reported to be activated by PRL-3 (Huang et al., 2014; Lian et al., 
2012; Park et al., 2013a; Qu et al., 2014), were blocked by specific inhibitors prior to 
CoCl2 treatment. However, unlike previous reports suggesting the involvement of these 
oncogenic pathways in cell survival (Buchheit et al., 2014), none of these pathways 
affected PRL-3-mediated cell survival upon inhibition.  
Since CoCl2 was reported to activate two pro-apoptosis pathways, JNK and p38 MAPK 
(Lan et al., 2011; Zou et al., 2002), the effects of PRL-3 on these two signalling pathways 
were examined. Interestingly, PRL-3 was found to significantly inhibit p38 MAPK 
activity in CoCl2-treated cells, but had no effect on JNK activity. Moreover, the p38 
inhibitor SB30580 effectively rescued CoCl2-induced cell shrinkage and loss of cell 
viability, which are two effects of PRL-3 overexpression, suggesting that p38 MAPK 
may participate in PRL-3-mediated anti-apoptotic effect. These findings showed a 
negative role of PRL-3 on p38 MAPK activation, which is generally consistent with 
previous report showing that p38 MAPK is activated upon knockdown of PRL-3 (Basak 
et al., 2008). However, there is also a contrasting study showing that PRL-3-induced 
phosphorylation of p38 MAPK (Al-Aidaroos et al., 2013). This inconsistency could be 
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due to the different conditions or different cell lines used. Unlike this study, the previous 
study detected the basal levels of p-p38 MAPK in A431 cells under nutrition abundant 
condition, but not the hyperactivated p38 status in DLD-1 cells upon stress stimuli. 
Therefore, a more systematic study, which includes different conditions and different cell 
lines, is required for a more comprehensive understanding in the future. 
p38 MAPK is a tumor suppressor which induces apoptosis in response to multiple stress 
conditions such as inflammatory stimulation, hyperosmosis, heat shock, UV irradiation, 
and oxidative stress (Cuenda and Rousseau, 2007). High ROS stimulates the 
ASK1-MKK cascade, resulting in activation of p38 MAPK (Hsieh and Papaconstantinou, 
2006). As CoCl2 is a ROS inducer, the effect of PRL-3 on intracellular ROS generation 
was assessed. Although ROS increased upon CoCl2 treatment, PRL-3 overexpression did 
not change the rate of ROS production. Consistently, the phosphorylation levels of 
ASK1and MKK4 increased upon CoCl2 treatment, but maintained similar levels upon 
PRL-3 overexpression, suggesting PRL-3-mediated inhibition of p38 AMPK is 
ROS-independent. Since PRL-3 promoted a loss of p38 MAPK phosphorylation without 
a reduction in the activity of the latter’s upstream kinases, the potential for PRL-3 to 
directly bind and dephosphorylate p38 MAPK was investigated. Indeed, an interaction 
between PRL-3 and p38 MAPK was observed in DLD-1 cells. Furthermore, PRL-3 could 
dephosphorylate p38 MAPK using an in vitro reaction with immunopurified p38. These 
results indicate that p38 MAPK might be a direct substrate of PRL-3.  
As yet, many DUSPs have been reported to bind and dephosphorylate MAPKs 
(Theodosiou and Ashworth, 2002). However, none of them have shown the unique 
specificity towards p38 MAPK; for example, DUSP8, DUSP10, and UUSP16 can 
dephosphorylate JNK in addition to p38 MAPK (Muda et al., 1996; Tanoue et al., 2001; 
Theodosiou et al., 1999). In contrast, PRL-3 appears highly specific for the inactivation 
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of p38 MAPK, and does not inhibit JNK activation under cellular stress. Although more 
experiments are needed to further validate these findings, this study suggests that p38 
MAPK might be a novel substrate of PRL-3 and PRL-3 may specifically dephosphorylate 
p38 MAPK under cellular stress to prevent apoptosis. 
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In this thesis, the functions and related mechanisms of PRL-3 in cancer development 
modulation were systematically investigated. Firstly, the key role of hyperactivated 
mTOR signalling in PRL-3-driven oncogenesis was described. Secondly, the synergy 
between Akt-TSC2-Rheb signalling and Rag GTPases in driving PRL-3-mediated mTOR 
hyperactivation was characterised. Finally, in a separate vein, a novel role of p38 MAPK 
in apoptosis resistance by PRL-3 was unravelled. A hypothetical model summarizing the 
findings herein is proposed in Figure 6.1. 
In the first part of the study, the relationship between PRL-3 expression and mTOR 
activity was investigated. Based on the positive correlation between PRL-3 expression 
and mTOR activity in vivo and in vitro, a causative link between elevated PRL-3 
expression and mTOR activation was subsequently found under both normal and stressed 
conditions. Importantly, PRL-3 sensitized cellular responses to rapamycin treatment, 
particularly cell growth, motility, and invasiveness. From a clinical perspective, these 
findings reveal an Achilles’ heel for PRL-3-overexpressing cancers, highlighting the 
possibility to target mTOR signalling in curtailing PRL-3-driven cancers. 
In the second part of the study, the mechanism underlying PRL-3-driven mTORC1 
activation was explored. Remarkably, PRL-3 induced mTORC1 activation via 2 parallel 
pathways: 1) activation of Akt-TSC2-Rheb signalling and 2) enhancement of Rag 
GTPase-mediated mTORC1 lysosomal recruitment. As yet, this is the first report of an 
mTORC1 regulator that affects both regulatory streams in parallel, effectively bringing 
activated Rheb (via Akt-TSC2) into proximity with mTORC1 at lysosomes (via Rag 
GTPase activity). This reveals the synergistic pathways PRL-3 function in oncogenesis, 
and cast some light into its reported pleiotropic effects. 
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Finally, in the third part of the study, the role of PRL-3 in CoCl2-induced apoptosis was 
investigated. PRL-3 endowed cells with the ability to survive challenge with high doses 
of CoCl2, even over prolonged periods, which was enough to kill cells without PRL-3 
overexpression. This was linked to a suppression of pro-apoptotic p38 MAPK activity, as 
inferred by the decrease in p38 MAPK phosphorylation in PRL-3-overexpressing cells, as 
well as the ability for a p38 MAPK inhibitor to suppress this pro-survival phenotype. 
Intriguingly, PRL-3 was found to bind p38 MAPK in cells, and could dephosphorylate 
p38 MAPK when reconstituted in an in vitro system, suggesting that p38 MAPK might 
be a bona fide PRL-3 substrate. Notably, a limitation of this study was the use of CoCl2 
to induce apoptosis - future work will require validation of the pro-survival response 
upon challenge with other physiologically-relevant apoptosis inducers. 
With pronounced overexpression in multiple human cancers and direct implication in 
tumour development, PRL-3 is regarded as a prognostic marker and a promising target 
for cancer therapy (Al-Aidaroos and Zeng, 2010). Although several PRL-3 inhibitors 
have been identified, none of them have reached clinical trials to date. Given the fact that 
mTOR is targeted pharmacologically in several pathologies, with several mTOR 
inhibitors already approved for cancer therapy (temsirolimus, everolimus), the finding of 
the critical role of mTOR in PRL-3-driven cancer progression more directly suggests a 
potential clinical value for mTOR inhibitors against PRL-3-overexpressing tumors, a 
hypothesis testable in future studies. Together with the advent of PRL-3-specific agents 
(Guo et al., 2011), further studies investigating the combinatorial value of drugs targeting 




Figure 6. 1 Proposed model of the regulatory role of PRL-3 in mTOR signalling and 
p38 MAPK signalling. PRL-3 promotes mTORC1 activation by (1) activating 
Akt-TSC2-Rheb cascades and (2) enhancing Rag GTPases-mediated mTORC1 
recruitment to lysosomes for activation, leading to an increase in cell motility, invasiveness, 
and MMP-2/9 production. (3) PRL-3 suppresses p38 MAPK activity to block apoptosis. 
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